Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Venlafaxine
- Accession Number
- DB00285 (APRD00125)
- Type
- Small Molecule
- Groups
- Approved
- Description
Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006. [Wikipedia]
- Structure
Structure for DB00285 (Venlafaxine)
- Synonyms
- Elafax
- Venlafaxina
- Venlafaxine
- Venlafaxinum
- Product Ingredients
Ingredient UNII CAS InChI Key Venlafaxine Hydrochloride 7D7RX5A8MO 99300-78-4 QYRYFNHXARDNFZ-UHFFFAOYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Act Venlafaxine XR Capsule, extended release 37.5 mg Oral Actavis Pharma Company 2008-02-13 Not applicable Canada 
Act Venlafaxine XR Capsule, extended release 150.0 mg Oral Actavis Pharma Company 2008-02-13 Not applicable Canada Act Venlafaxine XR Capsule, extended release 75.0 mg Oral Actavis Pharma Company 2008-02-13 Not applicable Canada Effexor Tablets, 37.5mg Tablet 37.5 mg Oral Wyeth Ltd. 1994-12-31 2004-08-19 Canada Effexor Tablets, 50mg Tablet 50 mg Oral Wyeth Ltd. 1995-12-31 2004-08-19 Canada Effexor Tablets, 75mg Tablet 75 mg Oral Wyeth Ltd. 1994-12-31 2004-08-19 Canada Effexor XR Capsule, extended release 75 mg/1 Oral Lake Erie Medical Dba Quality Care Produts Llc 2011-01-31 Not applicable US 
Effexor XR Capsule, extended release 75 mg Oral Pfizer 1998-03-04 Not applicable Canada Effexor XR Capsule, extended release 150 mg/1 Oral Cardinal Health 1997-11-01 2018-05-11 US Effexor XR Capsule, extended release 75 mg/1 Oral Remedy Repack 2016-05-22 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-venlafaxine XR Capsule, extended release 75 mg Oral Apotex Corporation 2013-04-16 Not applicable Canada Apo-venlafaxine XR Capsule, extended release 37.5 mg Oral Apotex Corporation 2013-04-16 Not applicable Canada Apo-venlafaxine XR Capsule, extended release 150 mg Oral Apotex Corporation 2013-04-16 Not applicable Canada Auro-venlafaxine XR Capsule, extended release 150 mg Oral Auro Pharma Inc 2016-03-14 Not applicable Canada Auro-venlafaxine XR Capsule, extended release 75 mg Oral Auro Pharma Inc 2016-03-14 Not applicable Canada Auro-venlafaxine XR Capsule, extended release 37.5 mg Oral Auro Pharma Inc 2016-03-14 Not applicable Canada Dom-venlafaxine XR Capsule, extended release 75 mg Oral Dominion Pharmacal 2013-05-23 Not applicable Canada Dom-venlafaxine XR Capsule, extended release 37.5 mg Oral Dominion Pharmacal 2013-05-23 Not applicable Canada Dom-venlafaxine XR Capsule, extended release 150 mg Oral Dominion Pharmacal 2013-05-30 Not applicable Canada Effexor Tablet 50 mg/1 Oral Directrx 2016-02-02 Not applicable US - International/Other Brands
- Effexor / Elafax
- Categories
- Alcohols
- Amines
- Antidepressive Agents, Second-Generation
- Central Nervous System Agents
- Central Nervous System Depressants
- Combined Inhibitors of Serotonin/Norepinephrine Reuptake
- Cyclohexanes
- Cyclohexanols
- Cycloparaffins
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (moderate)
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Ethylamines
- Fatty Alcohols
- Hexanols
- Lipids
- Membrane Transport Modulators
- Nervous System
- Neurotransmitter Agents
- Neurotransmitter Uptake Inhibitors
- P-glycoprotein/ABCB1 Inhibitors
- P-glycoprotein/ABCB1 Substrates
- Phenethylamines
- Potential QTc-Prolonging Agents
- Psychoanaleptics
- Psychotropic Drugs
- QTc Prolonging Agents
- Selective Serotonin and Noradrenaline Reuptake Inhibitors
- Selective Serotonin Reuptake Inhibitors
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin and Noradrenaline Reuptake Inhibitors
- Serotonin Modulators
- UNII
- GRZ5RCB1QG
- CAS number
- 93413-69-5
- Weight
- Average: 277.4018
Monoisotopic: 277.204179113 - Chemical Formula
- C17H27NO2
- InChI Key
- PNVNVHUZROJLTJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3
- IUPAC Name
- 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol
- SMILES
- COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Pharmacology
- Indication
For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.
- Associated Conditions
- Pharmacodynamics
Venlafaxine potentiates the neurotransmitter activity in the central nervous system. Furthermore, venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV) potently inhibit the reuptake of serotonin and norepinephrine and weakly inhibit dopamine reuptake. Both molecules do not bind to muscarinic, histaminergic, or alpha-1 adrenergic receptors. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs. Both also do not have any monoamine oxidase (MAO) inhibitory activity.
- Mechanism of action
The exact mechanism of action of venlafaxine is unknown, but appears to be associated with the its potentiation of neurotransmitter activity in the CNS. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), inhibit the reuptake of both serotonin and norepinephrine with a potency greater for the 5-HT than for the NE reuptake process. Both venlafaxine and the ODV metabolite have weak inhibitory effects on the reuptake of dopamine but, unlike the tricyclics and similar to SSRIs, they are not active at histaminergic, muscarinic, or alpha(1)-adrenergic receptors.
Target Actions Organism ASodium-dependent serotonin transporter inhibitorHuman ASodium-dependent noradrenaline transporter inhibitorHuman USodium-dependent dopamine transporter inhibitorHuman - Absorption
Venlafaxine is well absorbed. Food does not effect the absorption of venlafaxine or its subsequent metabolism into ODV. Bioavailability is 45% following oral administration. Time to steady state = 3 days.
- Volume of distribution
- 7.5 ± 3.7 L/kg Venlafaxine
- 5.7 ± 1.8 L/kg [O-desmethylvenlafaxine(active metabolite)]
- Protein binding
The degree of binding of venlafaxine to human plasma is 27% ± 2% at concentrations ranging from 2.5 to 2215 ng/mL. The degree of ODV binding to human plasma is 30% ± 12% at concentrations ranging from 100 to 500 ng/mL. Protein-binding-induced drug interactions with venlafaxine are not expected.
- Metabolism
Undergoes extensive first pass metabolism in the liver to its major, active metabolite, ODV, and two minor, less active metabolites, N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine. Formation of ODV is catalyzed by cytochrome P450 (CYP) 2D6, whereas N-demethylation is catalyzed by CYP3A4, 2C19 and 2C9. ODV possesses antidepressant activity that is comparable to that of venlfaxine.
- Route of elimination
Renal elimination of venlafaxine and its metabolites is the primary route of excretion. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).
- Half life
5 hours
- Clearance
Steady state plasma clearance, venlafaxine = 1.3 ± 0.6 L/h/kg; Steady state plasma clearance, ODV = 0.4 ± 0.2 L/h/kg.
- Toxicity
Most patients overdosing with venlafaxine develop only mild symptoms. However, severe toxicity is reported with the most common symptoms being CNS depression, serotonin toxicity, seizure, or cardiac conduction abnormalities. Venlafaxine's toxicity appears to be higher than other SSRIs, with a fatal toxic dose closer to that of the tricyclic antidepressants than the SSRIs. Doses of 900 mg or more are likely to cause moderate toxicity. Deaths have been reported following large doses.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Venlafaxine Metabolism Pathway Drug metabolism - Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Cytochrome P450 2D6 CYP2D6*4 (A;A) / (A;A) A Allele / A Allele Effect Directly Studied Patients with this genotype have reduced metabolism of venlafaxine. Details Cytochrome P450 2D6 CYP2D6*6 (-;-) / (-;T) / (-;-) T deletion / T deletion, homozygote Effect Directly Studied Patients with this genotype have reduced metabolism of venlafaxine. Details Cytochrome P450 2D6 CYP2D6*5 Not Available Whole gene deletion, homozygote Effect Directly Studied Patients with this genotype have reduced metabolism of venlafaxine. Details Multidrug resistance protein 1 --- (C;C) / (C;T) C Allele Effect Directly Studied Patients with this genotype have an increased likelihood of remission when using venlafaxine to treat major depressive disorder Details Multidrug resistance protein 1 --- (C;C) / (C;T) T > C Effect Directly Studied Patients with this genotype have increased risk of adverse events with venlafaxine Details Cytochrome P450 2D6 CYP2D6*3 Not Available C allele Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*7 Not Available 2935A>C Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*8 Not Available 1758G>T Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*11 Not Available 883G>C Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*12 Not Available 124G>A Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*13 Not Available CYP2D7/2D6 hybrid gene structure Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*14A Not Available 1758G>A Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*15 Not Available 137insT, 137_138insT Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*19 Not Available 2539_2542delAACT Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*20 Not Available 1973_1974insG Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*21 Not Available 2573insC Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*31 Not Available -1770G>A / -1584C>G … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*36 Not Available 100C>T / -1426C>T … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*38 Not Available 2587_2590delGACT Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*40 Not Available 1863_1864ins(TTT CGC CCC)2 Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*42 Not Available 3259_3260insGT Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*44 Not Available 2950G>C Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*47 Not Available 100C>T / -1426C>T … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*51 Not Available -1584C>G / -1235A>G … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*56 Not Available 3201C>T Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*57 Not Available 100C>T / 310G>T … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*62 Not Available 4044C>T Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*68A Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*68B Not Available Similar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4. Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*69 Not Available 2988G>A / -1426C>T … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*92 Not Available 1995delC Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*100 Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details Cytochrome P450 2D6 CYP2D6*101 Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer, lower dose requirements, nausea, vomiting and diarrhea Details
Interactions
- Drug Interactions
Drug Interaction Drug group 4-Methoxyamphetamine Venlafaxine may increase the tachycardic activities of 4-Methoxyamphetamine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Venlafaxine. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Venlafaxine. Experimental Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Venlafaxine. Approved, Investigational Abiraterone The serum concentration of Venlafaxine can be increased when it is combined with Abiraterone. Approved Acarbose Venlafaxine may increase the hypoglycemic activities of Acarbose. Approved, Investigational Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Venlafaxine. Approved, Investigational Aceclofenac Venlafaxine may increase the antiplatelet activities of Aceclofenac. Approved, Investigational Acenocoumarol The risk or severity of adverse effects can be increased when Venlafaxine is combined with Acenocoumarol. Approved, Investigational Acepromazine The risk or severity of adverse effects can be increased when Acepromazine is combined with Venlafaxine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Aceprometazine is combined with Venlafaxine. Approved Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Venlafaxine. Approved Acetophenazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Acetophenazine. Approved Acetyl sulfisoxazole The metabolism of Venlafaxine can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Acetylcholine The metabolism of Acetylcholine can be decreased when combined with Venlafaxine. Approved Acetylsalicylic acid Venlafaxine may increase the antiplatelet activities of Acetylsalicylic acid. Approved, Vet Approved Adinazolam The metabolism of Adinazolam can be decreased when combined with Venlafaxine. Approved Adipiplon The risk or severity of adverse effects can be increased when Adipiplon is combined with Venlafaxine. Investigational Adrafinil Venlafaxine may increase the tachycardic activities of Adrafinil. Withdrawn Afatinib The serum concentration of Afatinib can be increased when it is combined with Venlafaxine. Approved Agmatine Venlafaxine may increase the tachycardic activities of Agmatine. Experimental, Investigational Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Venlafaxine. Approved, Investigational Ajmaline The metabolism of Ajmaline can be decreased when combined with Venlafaxine. Approved, Investigational Alaproclate Venlafaxine may increase the serotonergic activities of Alaproclate. Experimental Albendazole The metabolism of Albendazole can be decreased when combined with Venlafaxine. Approved, Vet Approved Albiglutide Venlafaxine may increase the hypoglycemic activities of Albiglutide. Approved Alclometasone The metabolism of Alclometasone can be decreased when combined with Venlafaxine. Approved Alfaxalone The risk or severity of adverse effects can be increased when Alfaxalone is combined with Venlafaxine. Vet Approved Alfentanil The metabolism of Alfentanil can be decreased when combined with Venlafaxine. Approved, Illicit Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Venlafaxine. Approved, Investigational Aliskiren The metabolism of Aliskiren can be decreased when combined with Venlafaxine. Approved, Investigational Allopregnanolone The risk or severity of adverse effects can be increased when Allopregnanolone is combined with Venlafaxine. Investigational Allylestrenol The metabolism of Allylestrenol can be decreased when combined with Venlafaxine. Approved Almotriptan The risk or severity of adverse effects can be increased when Venlafaxine is combined with Almotriptan. Approved, Investigational Alogliptin The metabolism of Alogliptin can be decreased when combined with Venlafaxine. Approved Alosetron The metabolism of Alosetron can be decreased when combined with Venlafaxine. Approved, Withdrawn alpha-Tocopherol acetate The metabolism of alpha-Tocopherol acetate can be decreased when combined with Venlafaxine. Approved Alphacetylmethadol Alphacetylmethadol may increase the serotonergic activities of Venlafaxine. Experimental, Illicit Alphaprodine Alphaprodine may increase the serotonergic activities of Venlafaxine. Illicit Alprazolam The metabolism of Alprazolam can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational Alprenolol The metabolism of Alprenolol can be decreased when combined with Venlafaxine. Approved, Withdrawn Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Venlafaxine. Approved, Investigational Ambroxol The metabolism of Ambroxol can be decreased when combined with Venlafaxine. Approved, Investigational Amibegron Venlafaxine may increase the tachycardic activities of Amibegron. Investigational Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Venlafaxine. Approved, Withdrawn Aminophylline The metabolism of Aminophylline can be decreased when combined with Venlafaxine. Approved Aminosalicylic Acid Venlafaxine may increase the antiplatelet activities of Aminosalicylic Acid. Approved Amiodarone The metabolism of Venlafaxine can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Amisulpride is combined with Venlafaxine. Approved, Investigational Amitraz Venlafaxine may increase the tachycardic activities of Amitraz. Vet Approved Amitriptyline The risk or severity of adverse effects can be increased when Venlafaxine is combined with Amitriptyline. Approved Amlodipine The metabolism of Amlodipine can be decreased when combined with Venlafaxine. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Venlafaxine. Approved, Illicit Amoxapine Venlafaxine may increase the serotonergic activities of Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Amperozide is combined with Venlafaxine. Experimental Amphetamine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Amphetamine. Approved, Illicit, Investigational Amprenavir The metabolism of Amprenavir can be decreased when combined with Venlafaxine. Approved, Investigational Amsacrine The metabolism of Amsacrine can be decreased when combined with Venlafaxine. Approved, Investigational Anagrelide Venlafaxine may increase the QTc-prolonging activities of Anagrelide. Approved Anisodamine Venlafaxine may increase the tachycardic activities of Anisodamine. Investigational Antipyrine The metabolism of Antipyrine can be decreased when combined with Venlafaxine. Approved, Investigational Antrafenine Venlafaxine may increase the antiplatelet activities of Antrafenine. Approved Apalutamide The serum concentration of Venlafaxine can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The serum concentration of Apixaban can be increased when it is combined with Venlafaxine. Approved Apomorphine Venlafaxine may increase the tachycardic activities of Apomorphine. Approved, Investigational Apraclonidine Venlafaxine may increase the tachycardic activities of Apraclonidine. Approved Apremilast The metabolism of Apremilast can be decreased when combined with Venlafaxine. Approved, Investigational Aprepitant The serum concentration of Venlafaxine can be increased when it is combined with Aprepitant. Approved, Investigational Aprindine The metabolism of Aprindine can be decreased when combined with Venlafaxine. Approved Arbutamine Venlafaxine may increase the tachycardic activities of Arbutamine. Approved Arformoterol Venlafaxine may increase the tachycardic activities of Arformoterol. Approved, Investigational Argatroban The metabolism of Argatroban can be decreased when combined with Venlafaxine. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be increased when it is combined with Venlafaxine. Approved, Investigational Armodafinil The metabolism of Venlafaxine can be decreased when combined with Armodafinil. Approved, Investigational Arotinolol The serum concentration of Arotinolol can be increased when it is combined with Venlafaxine. Investigational Arsenic trioxide Venlafaxine may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Venlafaxine may increase the QTc-prolonging activities of Artemether. Approved Articaine The risk or severity of adverse effects can be increased when Articaine is combined with Venlafaxine. Approved Asenapine Venlafaxine may increase the QTc-prolonging activities of Asenapine. Approved Astemizole The metabolism of Astemizole can be decreased when combined with Venlafaxine. Approved, Withdrawn Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Venlafaxine. Approved, Investigational, Withdrawn Atazanavir The metabolism of Venlafaxine can be decreased when combined with Atazanavir. Approved, Investigational Atenolol The serum concentration of Atenolol can be increased when it is combined with Venlafaxine. Approved Atomoxetine The metabolism of Venlafaxine can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Venlafaxine is combined with Atorvastatin. Approved Avanafil The serum concentration of Avanafil can be increased when it is combined with Venlafaxine. Approved Avatrombopag The metabolism of Avatrombopag can be decreased when combined with Venlafaxine. Approved, Investigational Axitinib The metabolism of Axitinib can be decreased when combined with Venlafaxine. Approved, Investigational Azaperone The risk or severity of adverse effects can be increased when Azaperone is combined with Venlafaxine. Investigational, Vet Approved Azelastine The metabolism of Azelastine can be decreased when combined with Venlafaxine. Approved Azithromycin The metabolism of Azithromycin can be decreased when combined with Venlafaxine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Venlafaxine. Approved Balsalazide Venlafaxine may increase the antiplatelet activities of Balsalazide. Approved, Investigational Bambuterol Venlafaxine may increase the tachycardic activities of Bambuterol. Approved, Investigational Banoxantrone The metabolism of Banoxantrone can be decreased when combined with Venlafaxine. Investigational Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Venlafaxine. Illicit Baricitinib The metabolism of Baricitinib can be decreased when combined with Venlafaxine. Approved, Investigational Bedaquiline The metabolism of Bedaquiline can be decreased when combined with Venlafaxine. Approved Befunolol Venlafaxine may increase the tachycardic activities of Befunolol. Experimental Bendroflumethiazide Venlafaxine may increase the hyponatremic activities of Bendroflumethiazide. Approved Benidipine The metabolism of Benidipine can be decreased when combined with Venlafaxine. Approved, Investigational Benmoxin The risk or severity of adverse effects can be increased when Venlafaxine is combined with Benmoxin. Withdrawn Benperidol The risk or severity of adverse effects can be increased when Benperidol is combined with Venlafaxine. Approved, Investigational Benzatropine The metabolism of Benzatropine can be decreased when combined with Venlafaxine. Approved Benzocaine The risk or severity of adverse effects can be increased when Benzocaine is combined with Venlafaxine. Approved, Investigational Benzphetamine Venlafaxine may increase the tachycardic activities of Benzphetamine. Approved, Illicit Benzthiazide Venlafaxine may increase the hyponatremic activities of Benzthiazide. Approved Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Venlafaxine. Approved Bepridil The metabolism of Bepridil can be decreased when combined with Venlafaxine. Approved, Withdrawn Betaxolol The metabolism of Betaxolol can be decreased when combined with Venlafaxine. Approved, Investigational Bethanidine Venlafaxine may decrease the antihypertensive activities of Bethanidine. Approved Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Venlafaxine. Approved, Investigational Bevantolol The serum concentration of Bevantolol can be increased when it is combined with Venlafaxine. Approved Bexarotene The metabolism of Bexarotene can be decreased when combined with Venlafaxine. Approved, Investigational Bezafibrate The metabolism of Bezafibrate can be decreased when combined with Venlafaxine. Approved, Investigational Bezitramide Bezitramide may increase the serotonergic activities of Venlafaxine. Experimental, Illicit, Withdrawn Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Venlafaxine. Approved Bictegravir The metabolism of Bictegravir can be decreased when combined with Venlafaxine. Approved, Investigational Bifeprunox The risk or severity of adverse effects can be increased when Venlafaxine is combined with Bifeprunox. Investigational Bioallethrin The metabolism of Bioallethrin can be decreased when combined with Venlafaxine. Approved, Experimental Bisoprolol The metabolism of Bisoprolol can be decreased when combined with Venlafaxine. Approved Bitolterol Venlafaxine may increase the tachycardic activities of Bitolterol. Withdrawn Blonanserin The metabolism of Blonanserin can be decreased when combined with Venlafaxine. Approved, Investigational Boceprevir The metabolism of Venlafaxine can be decreased when combined with Boceprevir. Approved, Withdrawn Bopindolol The serum concentration of Bopindolol can be increased when it is combined with Venlafaxine. Approved Bortezomib The metabolism of Venlafaxine can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Bosentan can be increased when it is combined with Venlafaxine. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Venlafaxine. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Venlafaxine. Approved, Investigational Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Venlafaxine. Approved, Investigational Brigatinib The metabolism of Brigatinib can be decreased when combined with Venlafaxine. Approved, Investigational Brimonidine Venlafaxine may increase the tachycardic activities of Brimonidine. Approved Brinzolamide The metabolism of Brinzolamide can be decreased when combined with Venlafaxine. Approved Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Venlafaxine. Approved, Investigational Brofaromine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Brofaromine. Experimental Bromazepam The metabolism of Bromazepam can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational Bromfenac Venlafaxine may increase the antiplatelet activities of Bromfenac. Approved Bromisoval The risk or severity of adverse effects can be increased when Bromisoval is combined with Venlafaxine. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Venlafaxine. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Bromperidol is combined with Venlafaxine. Approved, Investigational Brompheniramine The metabolism of Brompheniramine can be decreased when combined with Venlafaxine. Approved Brotizolam The risk or severity of adverse effects can be increased when Brotizolam is combined with Venlafaxine. Approved, Investigational, Withdrawn Bucindolol The serum concentration of Bucindolol can be increased when it is combined with Venlafaxine. Investigational Budesonide The serum concentration of Budesonide can be increased when it is combined with Venlafaxine. Approved Bufexamac Venlafaxine may increase the antiplatelet activities of Bufexamac. Approved, Experimental Bufuralol The metabolism of Bufuralol can be decreased when combined with Venlafaxine. Experimental, Investigational Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Venlafaxine. Approved, Investigational Bupranolol The serum concentration of Bupranolol can be increased when it is combined with Venlafaxine. Approved Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational, Vet Approved Bupropion The serum concentration of Bupropion can be increased when it is combined with Venlafaxine. Approved Buspirone Buspirone may increase the serotonergic activities of Venlafaxine. Approved, Investigational Busulfan The metabolism of Busulfan can be decreased when combined with Venlafaxine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Butacaine is combined with Venlafaxine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Venlafaxine. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Butamben is combined with Venlafaxine. Approved, Withdrawn Butaperazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Butaperazine. Experimental Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Venlafaxine. Approved, Illicit Butorphanol Butorphanol may increase the serotonergic activities of Venlafaxine. Approved, Illicit, Vet Approved Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Venlafaxine. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Venlafaxine. Approved Cabozantinib The metabolism of Cabozantinib can be decreased when combined with Venlafaxine. Approved, Investigational Caffeine The metabolism of Caffeine can be decreased when combined with Venlafaxine. Approved Calcitriol The metabolism of Calcitriol can be decreased when combined with Venlafaxine. Approved, Nutraceutical Canagliflozin The metabolism of Canagliflozin can be decreased when combined with Venlafaxine. Approved Canertinib The risk or severity of adverse effects can be increased when Canertinib is combined with Venlafaxine. Investigational Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Venlafaxine. Approved, Investigational Capecitabine The metabolism of Venlafaxine can be decreased when combined with Capecitabine. Approved, Investigational Capsaicin Venlafaxine may increase the antiplatelet activities of Capsaicin. Approved Captopril The metabolism of Captopril can be decreased when combined with Venlafaxine. Approved Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Venlafaxine. Approved, Investigational Carbinoxamine The metabolism of Carbinoxamine can be decreased when combined with Venlafaxine. Approved Carfentanil Carfentanil may increase the serotonergic activities of Venlafaxine. Illicit, Investigational, Vet Approved Cariprazine The metabolism of Cariprazine can be decreased when combined with Venlafaxine. Approved, Investigational Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Venlafaxine. Approved Caroxazone The risk or severity of adverse effects can be increased when Venlafaxine is combined with Caroxazone. Withdrawn Carprofen Venlafaxine may increase the antiplatelet activities of Carprofen. Approved, Vet Approved, Withdrawn Carteolol The metabolism of Carteolol can be decreased when combined with Venlafaxine. Approved Carvedilol The metabolism of Carvedilol can be decreased when combined with Venlafaxine. Approved, Investigational Celecoxib Venlafaxine may increase the antiplatelet activities of Celecoxib. Approved, Investigational Celiprolol Venlafaxine may increase the tachycardic activities of Celiprolol. Approved, Investigational Cephalexin The metabolism of Cephalexin can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Venlafaxine can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Venlafaxine. Approved, Withdrawn Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Venlafaxine. Approved Cevimeline The metabolism of Cevimeline can be decreased when combined with Venlafaxine. Approved Chenodeoxycholic acid The metabolism of Chenodeoxycholic acid can be decreased when combined with Venlafaxine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Venlafaxine. Approved, Illicit, Investigational, Vet Approved Chloramphenicol The metabolism of Venlafaxine can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The metabolism of Chlordiazepoxide can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Venlafaxine. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Venlafaxine. Approved Chloroquine The metabolism of Chloroquine can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Chlorothiazide Venlafaxine may increase the hyponatremic activities of Chlorothiazide. Approved, Vet Approved Chlorphenamine The metabolism of Chlorphenamine can be decreased when combined with Venlafaxine. Approved Chlorphenesin Venlafaxine may increase the antiplatelet activities of Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorproethazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Chlorproethazine. Experimental Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Chlorpropamide Venlafaxine may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Venlafaxine. Approved, Investigational, Withdrawn Chlorthalidone Venlafaxine may increase the hyponatremic activities of Chlorthalidone. Approved Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Venlafaxine. Approved Cholecalciferol The metabolism of Cholecalciferol can be decreased when combined with Venlafaxine. Approved, Nutraceutical Choline magnesium trisalicylate Venlafaxine may increase the antiplatelet activities of Choline magnesium trisalicylate. Approved Ciclesonide The metabolism of Ciclesonide can be decreased when combined with Venlafaxine. Approved, Investigational Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Venlafaxine. Approved, Investigational Cimetidine The metabolism of Venlafaxine can be decreased when combined with Cimetidine. Approved, Investigational Cimicoxib Venlafaxine may increase the antiplatelet activities of Cimicoxib. Investigational Cinacalcet The metabolism of Venlafaxine can be decreased when combined with Cinacalcet. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Venlafaxine. Approved, Vet Approved Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Venlafaxine. Approved, Investigational Ciprofloxacin Venlafaxine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cirazoline Venlafaxine may increase the tachycardic activities of Cirazoline. Experimental Cisapride Venlafaxine may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Cisplatin Venlafaxine may increase the antiplatelet activities of Cisplatin. Approved Citalopram Venlafaxine may increase the serotonergic activities of Citalopram. Approved Clarithromycin The metabolism of Venlafaxine can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Venlafaxine can be decreased when combined with Clemastine. Approved, Investigational Clenbuterol Venlafaxine may increase the tachycardic activities of Clenbuterol. Approved, Investigational, Vet Approved Clevidipine The metabolism of Clevidipine can be decreased when combined with Venlafaxine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Venlafaxine. Approved Clindamycin The metabolism of Clindamycin can be decreased when combined with Venlafaxine. Approved, Vet Approved Clobazam The metabolism of Clobazam can be decreased when combined with Venlafaxine. Approved, Illicit Clodronic Acid Venlafaxine may increase the antiplatelet activities of Clodronic Acid. Approved, Investigational, Vet Approved Clofazimine The metabolism of Clofazimine can be decreased when combined with Venlafaxine. Approved, Investigational Clofibrate The metabolism of Clofibrate can be decreased when combined with Venlafaxine. Approved, Investigational clomethiazole The metabolism of clomethiazole can be decreased when combined with Venlafaxine. Investigational Clomipramine Venlafaxine may increase the serotonergic activities of Clomipramine. Approved, Investigational, Vet Approved Clonazepam The metabolism of Clonazepam can be decreased when combined with Venlafaxine. Approved, Illicit Clonidine Venlafaxine may increase the tachycardic activities of Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Clopenthixol is combined with Venlafaxine. Experimental Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Venlafaxine. Approved Cloranolol The serum concentration of Cloranolol can be increased when it is combined with Venlafaxine. Experimental Clorazepate The metabolism of Clorazepate can be decreased when combined with Venlafaxine. Approved, Illicit Clorindione The risk or severity of adverse effects can be increased when Venlafaxine is combined with Clorindione. Experimental Clothiapine The risk or severity of adverse effects can be increased when Clothiapine is combined with Venlafaxine. Experimental Clotiazepam The metabolism of Clotiazepam can be decreased when combined with Venlafaxine. Approved, Illicit Clotrimazole The metabolism of Venlafaxine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The serum concentration of Clozapine can be increased when it is combined with Venlafaxine. Approved Cobicistat The serum concentration of Venlafaxine can be increased when it is combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Venlafaxine. Approved, Investigational Cocaine The metabolism of Venlafaxine can be decreased when combined with Cocaine. Approved, Illicit Codeine The therapeutic efficacy of Codeine can be decreased when used in combination with Venlafaxine. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Venlafaxine. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Venlafaxine. Approved, Investigational Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Venlafaxine. Approved Copanlisib The metabolism of Copanlisib can be decreased when combined with Venlafaxine. Approved, Investigational Cortisone acetate The metabolism of Cortisone acetate can be decreased when combined with Venlafaxine. Approved, Investigational Crisaborole The metabolism of Venlafaxine can be decreased when combined with Crisaborole. Approved, Investigational Crizotinib The metabolism of Crizotinib can be decreased when combined with Venlafaxine. Approved Curcumin The metabolism of Venlafaxine can be decreased when combined with Curcumin. Approved, Investigational Cyamemazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyamemazine. Approved Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Venlafaxine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyclobenzaprine. Approved Cyclopenthiazide Venlafaxine may increase the hyponatremic activities of Cyclopenthiazide. Experimental Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Venlafaxine. Approved, Investigational Cyclopropane The risk or severity of adverse effects can be increased when Cyclopropane is combined with Venlafaxine. Experimental Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Cyproheptadine The therapeutic efficacy of Venlafaxine can be decreased when used in combination with Cyproheptadine. Approved Cytarabine The metabolism of Cytarabine can be decreased when combined with Venlafaxine. Approved, Investigational Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Venlafaxine. Approved Dabrafenib The serum concentration of Venlafaxine can be decreased when it is combined with Dabrafenib. Approved, Investigational Daclatasvir The metabolism of Daclatasvir can be decreased when combined with Venlafaxine. Approved, Investigational Dantrolene The metabolism of Dantrolene can be decreased when combined with Venlafaxine. Approved, Investigational Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Venlafaxine. Approved Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Venlafaxine. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dapoxetine is combined with Venlafaxine. Investigational Dapsone The metabolism of Dapsone can be decreased when combined with Venlafaxine. Approved, Investigational Darifenacin The metabolism of Darifenacin can be decreased when combined with Venlafaxine. Approved, Investigational Darunavir The serum concentration of Venlafaxine can be increased when it is combined with Darunavir. Approved Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Venlafaxine. Approved Dasatinib The serum concentration of Venlafaxine can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The metabolism of Daunorubicin can be decreased when combined with Venlafaxine. Approved Debrisoquin The metabolism of Debrisoquin can be decreased when combined with Venlafaxine. Approved, Investigational Deferasirox The serum concentration of Venlafaxine can be decreased when it is combined with Deferasirox. Approved, Investigational Deflazacort The metabolism of Deflazacort can be decreased when combined with Venlafaxine. Approved, Investigational Delamanid The metabolism of Delamanid can be decreased when combined with Venlafaxine. Approved, Investigational Delavirdine The metabolism of Venlafaxine can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Deramciclane is combined with Venlafaxine. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Venlafaxine. Approved Desipramine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine. Approved, Investigational Desmopressin The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin. Approved Desvenlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desvenlafaxine. Approved, Investigational Detomidine Venlafaxine may increase the tachycardic activities of Detomidine. Vet Approved Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Venlafaxine. Approved, Investigational Dexamethasone The metabolism of Dexamethasone can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Venlafaxine. Approved Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Venlafaxine. Approved Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational, Withdrawn Dexibuprofen Venlafaxine may increase the antiplatelet activities of Dexibuprofen. Approved, Investigational Dexketoprofen Venlafaxine may increase the antiplatelet activities of Dexketoprofen. Approved, Investigational Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Venlafaxine. Approved, Investigational Dexmedetomidine Venlafaxine may increase the tachycardic activities of Dexmedetomidine. Approved, Vet Approved Dexmethylphenidate The metabolism of Dexmethylphenidate can be decreased when combined with Venlafaxine. Approved, Investigational Dextroamphetamine The metabolism of Dextroamphetamine can be decreased when combined with Venlafaxine. Approved, Illicit Dextromethorphan Venlafaxine may increase the serotonergic activities of Dextromethorphan. Approved Dextromoramide Dextromoramide may increase the serotonergic activities of Venlafaxine. Experimental, Illicit Dextropropoxyphene The metabolism of Dextropropoxyphene can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational, Withdrawn Dezocine Dezocine may increase the serotonergic activities of Venlafaxine. Approved, Investigational Diazepam The metabolism of Diazepam can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational, Vet Approved Diclofenac The metabolism of Diclofenac can be decreased when combined with Venlafaxine. Approved, Vet Approved Dicoumarol The risk or severity of adverse effects can be increased when Venlafaxine is combined with Dicoumarol. Approved Dienogest The metabolism of Dienogest can be decreased when combined with Venlafaxine. Approved Diethyl ether The risk or severity of adverse effects can be increased when Diethyl ether is combined with Venlafaxine. Experimental Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Venlafaxine. Approved, Illicit Diflunisal Venlafaxine may increase the antiplatelet activities of Diflunisal. Approved, Investigational Digitoxin The metabolism of Digitoxin can be decreased when combined with Venlafaxine. Approved, Investigational Digoxin The metabolism of Digoxin can be decreased when combined with Venlafaxine. Approved Dihydro-alpha-ergocryptine The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Venlafaxine. Approved Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Venlafaxine. Approved, Illicit Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Venlafaxine. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Venlafaxine. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Venlafaxine. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Venlafaxine. Approved, Investigational Dihydroetorphine Dihydroetorphine may increase the serotonergic activities of Venlafaxine. Experimental, Illicit Dihydromorphine Dihydromorphine may increase the serotonergic activities of Venlafaxine. Experimental, Illicit Diltiazem The metabolism of Venlafaxine can be decreased when combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine. Approved Diphenadione The risk or severity of adverse effects can be increased when Venlafaxine is combined with Diphenadione. Experimental Diphenhydramine The metabolism of Diphenhydramine can be decreased when combined with Venlafaxine. Approved, Investigational Diphenoxylate Diphenoxylate may increase the serotonergic activities of Venlafaxine. Approved, Illicit Dipivefrin Venlafaxine may increase the tachycardic activities of Dipivefrin. Approved Disopyramide Venlafaxine may increase the QTc-prolonging activities of Disopyramide. Approved Disulfiram The metabolism of Disulfiram can be decreased when combined with Venlafaxine. Approved Dixyrazine The risk or severity of adverse effects can be increased when Dixyrazine is combined with Venlafaxine. Experimental DL-Methylephedrine Venlafaxine may increase the tachycardic activities of DL-Methylephedrine. Approved Dobutamine Venlafaxine may increase the tachycardic activities of Dobutamine. Approved Docetaxel The metabolism of Docetaxel can be decreased when combined with Venlafaxine. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be increased when it is combined with Venlafaxine. Approved, Investigational Dolasetron The metabolism of Dolasetron can be decreased when combined with Venlafaxine. Approved, Investigational Domperidone The serum concentration of Domperidone can be increased when it is combined with Venlafaxine. Approved, Investigational, Vet Approved Donepezil The metabolism of Donepezil can be decreased when combined with Venlafaxine. Approved Dopamine The metabolism of Dopamine can be decreased when combined with Venlafaxine. Approved Dopexamine Venlafaxine may increase the tachycardic activities of Dopexamine. Approved, Investigational Doramectin The risk or severity of adverse effects can be increased when Doramectin is combined with Venlafaxine. Vet Approved Dorzolamide The metabolism of Dorzolamide can be decreased when combined with Venlafaxine. Approved Dosulepin The serum concentration of Dosulepin can be increased when it is combined with Venlafaxine. Approved Doxazosin The metabolism of Doxazosin can be decreased when combined with Venlafaxine. Approved Doxepin The risk or severity of adverse effects can be increased when Venlafaxine is combined with Doxepin. Approved, Investigational Doxofylline Venlafaxine may increase the tachycardic activities of Doxofylline. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Venlafaxine. Approved, Investigational Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Venlafaxine. Approved, Investigational Doxycycline The metabolism of Venlafaxine can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine The risk or severity of adverse effects can be increased when Doxylamine is combined with Venlafaxine. Approved, Vet Approved DPDPE DPDPE may increase the serotonergic activities of Venlafaxine. Experimental Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Venlafaxine. Approved, Illicit Dronedarone Venlafaxine may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol The risk or severity of adverse effects can be increased when Droperidol is combined with Venlafaxine. Approved, Vet Approved Drospirenone Venlafaxine may increase the antiplatelet activities of Drospirenone. Approved Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Venlafaxine. Experimental, Illicit Droxicam Venlafaxine may increase the antiplatelet activities of Droxicam. Withdrawn Droxidopa Venlafaxine may increase the tachycardic activities of Droxidopa. Approved, Investigational Dulaglutide Venlafaxine may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Duloxetine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Duloxetine. Approved Dutasteride The metabolism of Dutasteride can be decreased when combined with Venlafaxine. Approved, Investigational Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Venlafaxine. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Venlafaxine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Ecopipam is combined with Venlafaxine. Investigational Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Venlafaxine. Approved Efavirenz The metabolism of Efavirenz can be decreased when combined with Venlafaxine. Approved, Investigational Elbasvir The metabolism of Elbasvir can be decreased when combined with Venlafaxine. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Venlafaxine. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Venlafaxine. Approved Eltanolone The risk or severity of adverse effects can be increased when Eltanolone is combined with Venlafaxine. Investigational Elvitegravir The metabolism of Elvitegravir can be decreased when combined with Venlafaxine. Approved Empagliflozin Venlafaxine may increase the hypoglycemic activities of Empagliflozin. Approved Enalapril The metabolism of Enalapril can be decreased when combined with Venlafaxine. Approved, Vet Approved Enasidenib The metabolism of Enasidenib can be decreased when combined with Venlafaxine. Approved, Investigational Encainide The metabolism of Encainide can be decreased when combined with Venlafaxine. Approved, Investigational, Withdrawn Enclomiphene The metabolism of Enclomiphene can be decreased when combined with Venlafaxine. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Venlafaxine. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Venlafaxine. Approved, Investigational Enzalutamide The serum concentration of Venlafaxine can be decreased when it is combined with Enzalutamide. Approved Epanolol The serum concentration of Epanolol can be increased when it is combined with Venlafaxine. Experimental Ephedra Venlafaxine may increase the tachycardic activities of Ephedra. Approved, Nutraceutical, Withdrawn Ephedrine Venlafaxine may increase the tachycardic activities of Ephedrine. Approved Epinastine Venlafaxine may increase the tachycardic activities of Epinastine. Approved, Investigational Epinephrine Venlafaxine may increase the tachycardic activities of Epinephrine. Approved, Vet Approved Epitizide Venlafaxine may increase the hyponatremic activities of Epitizide. Experimental Eplerenone The serum concentration of Eplerenone can be increased when it is combined with Venlafaxine. Approved Ergocalciferol The metabolism of Ergocalciferol can be decreased when combined with Venlafaxine. Approved, Nutraceutical Ergoloid mesylate The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergoloid mesylate. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Venlafaxine. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Venlafaxine. Approved Erlotinib The metabolism of Erlotinib can be decreased when combined with Venlafaxine. Approved, Investigational Erythromycin The metabolism of Venlafaxine can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Esatenolol The serum concentration of Esatenolol can be increased when it is combined with Venlafaxine. Experimental Escitalopram Venlafaxine may increase the serotonergic activities of Escitalopram. Approved, Investigational Eslicarbazepine acetate The metabolism of Venlafaxine can be decreased when combined with Eslicarbazepine acetate. Approved Esmirtazapine The metabolism of Esmirtazapine can be decreased when combined with Venlafaxine. Investigational Esmolol The serum concentration of Esmolol can be increased when it is combined with Venlafaxine. Approved Esomeprazole The metabolism of Esomeprazole can be decreased when combined with Venlafaxine. Approved, Investigational Estazolam The metabolism of Estazolam can be decreased when combined with Venlafaxine. Approved, Illicit Estradiol The metabolism of Estradiol can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Estramustine The metabolism of Estramustine can be decreased when combined with Venlafaxine. Approved, Investigational Estrogens, esterified The metabolism of Estrogens, esterified can be decreased when combined with Venlafaxine. Approved Estrone The metabolism of Estrone can be decreased when combined with Venlafaxine. Approved Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Venlafaxine. Approved Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Venlafaxine. Approved, Investigational Etafedrine Venlafaxine may increase the tachycardic activities of Etafedrine. Approved Etanercept Venlafaxine may increase the antiplatelet activities of Etanercept. Approved, Investigational Ethanol The risk or severity of adverse effects can be increased when Ethanol is combined with Venlafaxine. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine. Approved, Illicit, Withdrawn Ethinyl Estradiol The metabolism of Ethinyl Estradiol can be decreased when combined with Venlafaxine. Approved Ethosuximide The metabolism of Ethosuximide can be decreased when combined with Venlafaxine. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Venlafaxine. Approved Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Venlafaxine is combined with Ethyl biscoumacetate. Withdrawn Ethyl carbamate The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Venlafaxine. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Ethyl chloride is combined with Venlafaxine. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Venlafaxine. Approved, Illicit Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Venlafaxine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Etidocaine is combined with Venlafaxine. Approved Etifoxine The risk or severity of adverse effects can be increased when Etifoxine is combined with Venlafaxine. Investigational, Withdrawn Etilefrine Venlafaxine may increase the tachycardic activities of Etilefrine. Withdrawn Etizolam The risk or severity of adverse effects can be increased when Etizolam is combined with Venlafaxine. Approved Etodolac Venlafaxine may increase the antiplatelet activities of Etodolac. Approved, Investigational, Vet Approved Etomidate Venlafaxine may increase the tachycardic activities of Etomidate. Approved Etonogestrel The metabolism of Etonogestrel can be decreased when combined with Venlafaxine. Approved, Investigational Etoposide The metabolism of Etoposide can be decreased when combined with Venlafaxine. Approved Etoricoxib Venlafaxine may increase the antiplatelet activities of Etoricoxib. Approved, Investigational Etorphine Etorphine may increase the serotonergic activities of Venlafaxine. Illicit, Vet Approved Etravirine The metabolism of Etravirine can be decreased when combined with Venlafaxine. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Venlafaxine. Approved Exemestane The metabolism of Exemestane can be decreased when combined with Venlafaxine. Approved, Investigational Exenatide Venlafaxine may increase the hypoglycemic activities of Exenatide. Approved, Investigational Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Venlafaxine. Approved, Investigational Famciclovir The metabolism of Famciclovir can be decreased when combined with Venlafaxine. Approved, Investigational Felbamate The metabolism of Felbamate can be decreased when combined with Venlafaxine. Approved Felodipine The metabolism of Felodipine can be decreased when combined with Venlafaxine. Approved, Investigational Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Venlafaxine. Approved, Illicit, Withdrawn Fenfluramine Venlafaxine may increase the serotonergic activities of Fenfluramine. Approved, Illicit, Investigational, Withdrawn Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Venlafaxine. Approved Fenoprofen Venlafaxine may increase the antiplatelet activities of Fenoprofen. Approved Fenoterol Venlafaxine may increase the tachycardic activities of Fenoterol. Approved, Investigational Fentanyl The serum concentration of Fentanyl can be increased when it is combined with Venlafaxine. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Venlafaxine. Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Venlafaxine. Approved, Investigational Finasteride The metabolism of Finasteride can be decreased when combined with Venlafaxine. Approved Fingolimod The metabolism of Fingolimod can be decreased when combined with Venlafaxine. Approved, Investigational Fish oil Venlafaxine may increase the antiplatelet activities of Fish oil. Approved, Nutraceutical Flecainide The metabolism of Flecainide can be decreased when combined with Venlafaxine. Approved, Withdrawn Flibanserin The risk or severity of adverse effects can be increased when Venlafaxine is combined with Flibanserin. Approved, Investigational Floxuridine The metabolism of Venlafaxine can be decreased when combined with Floxuridine. Approved Fluanisone The risk or severity of adverse effects can be increased when Fluanisone is combined with Venlafaxine. Experimental Fluconazole The metabolism of Venlafaxine can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Venlafaxine. Approved, Illicit Fluindione The risk or severity of adverse effects can be increased when Venlafaxine is combined with Fluindione. Approved, Investigational Flunarizine The metabolism of Flunarizine can be decreased when combined with Venlafaxine. Approved Flunisolide The metabolism of Flunisolide can be decreased when combined with Venlafaxine. Approved, Investigational Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Venlafaxine. Approved, Illicit Fluorometholone The metabolism of Fluorometholone can be decreased when combined with Venlafaxine. Approved, Investigational Fluorouracil The metabolism of Venlafaxine can be decreased when combined with Fluorouracil. Approved Fluoxetine The metabolism of Venlafaxine can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol Venlafaxine may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The metabolism of Fluphenazine can be decreased when combined with Venlafaxine. Approved Flurazepam The metabolism of Flurazepam can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational Flurbiprofen Venlafaxine may increase the antiplatelet activities of Flurbiprofen. Approved, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Fluspirilene is combined with Venlafaxine. Approved, Investigational Flutamide The metabolism of Flutamide can be decreased when combined with Venlafaxine. Approved, Investigational Fluticasone furoate The metabolism of Fluticasone furoate can be decreased when combined with Venlafaxine. Approved Fluticasone propionate The metabolism of Fluticasone propionate can be decreased when combined with Venlafaxine. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Venlafaxine. Approved Fluvoxamine The metabolism of Venlafaxine can be decreased when combined with Fluvoxamine. Approved, Investigational Formoterol Venlafaxine may increase the tachycardic activities of Formoterol. Approved, Investigational Fosamprenavir The metabolism of Venlafaxine can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Venlafaxine can be increased when it is combined with Fosaprepitant. Approved Fosnetupitant The metabolism of Fosnetupitant can be decreased when combined with Venlafaxine. Approved Fosphenytoin The metabolism of Venlafaxine can be increased when combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Fospropofol is combined with Venlafaxine. Approved, Illicit, Investigational Fostamatinib The metabolism of Fostamatinib can be decreased when combined with Venlafaxine. Approved, Investigational Frovatriptan The risk or severity of adverse effects can be increased when Venlafaxine is combined with Frovatriptan. Approved, Investigational Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Venlafaxine. Approved, Investigational Furazolidone Furazolidone may increase the serotonergic activities of Venlafaxine. Approved, Investigational, Vet Approved Fusidic Acid The serum concentration of Venlafaxine can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Venlafaxine. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Venlafaxine. Approved, Investigational Gadobenic acid Venlafaxine may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Galantamine The metabolism of Galantamine can be decreased when combined with Venlafaxine. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Venlafaxine. Approved, Illicit, Investigational Gefitinib The metabolism of Gefitinib can be decreased when combined with Venlafaxine. Approved, Investigational Gemfibrozil The metabolism of Venlafaxine can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Venlafaxine may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Gepirone The risk or severity of adverse effects can be increased when Gepirone is combined with Venlafaxine. Investigational Ginseng Venlafaxine may increase the antiplatelet activities of Ginseng. Approved, Investigational, Nutraceutical Gliclazide Venlafaxine may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Venlafaxine may increase the hypoglycemic activities of Glimepiride. Approved Glipizide The metabolism of Glipizide can be decreased when combined with Venlafaxine. Approved, Investigational Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Venlafaxine. Approved, Illicit Glyburide The metabolism of Glyburide can be decreased when combined with Venlafaxine. Approved Goserelin Venlafaxine may increase the QTc-prolonging activities of Goserelin. Approved Granisetron The metabolism of Granisetron can be decreased when combined with Venlafaxine. Approved, Investigational Grazoprevir The metabolism of Grazoprevir can be decreased when combined with Venlafaxine. Approved Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Venlafaxine. Approved, Investigational, Withdrawn Guanabenz Venlafaxine may increase the tachycardic activities of Guanabenz. Approved, Investigational Guanfacine Venlafaxine may increase the tachycardic activities of Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Venlafaxine. Approved, Illicit, Withdrawn Halofantrine The serum concentration of Halofantrine can be increased when it is combined with Venlafaxine. Approved Haloperidol The metabolism of Haloperidol can be decreased when combined with Venlafaxine. Approved Halothane The metabolism of Halothane can be decreased when combined with Venlafaxine. Approved, Vet Approved Harmaline The risk or severity of adverse effects can be increased when Venlafaxine is combined with Harmaline. Experimental Heroin Heroin may increase the serotonergic activities of Venlafaxine. Approved, Illicit, Investigational Hexobarbital The metabolism of Hexobarbital can be decreased when combined with Venlafaxine. Approved Hexoprenaline Venlafaxine may increase the tachycardic activities of Hexoprenaline. Approved, Withdrawn Higenamine Venlafaxine may increase the tachycardic activities of Higenamine. Investigational Histamine The metabolism of Histamine can be decreased when combined with Venlafaxine. Approved, Investigational Hydracarbazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Hydracarbazine. Experimental Hydrochlorothiazide Venlafaxine may increase the hyponatremic activities of Hydrochlorothiazide. Approved, Vet Approved Hydrocodone The serum concentration of Hydrocodone can be increased when it is combined with Venlafaxine. Approved, Illicit Hydrocortisone The metabolism of Hydrocortisone can be decreased when combined with Venlafaxine. Approved, Vet Approved Hydroflumethiazide Venlafaxine may increase the hyponatremic activities of Hydroflumethiazide. Approved, Investigational Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Venlafaxine. Approved, Illicit Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Venlafaxine. Approved, Investigational Hydroxyzine The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Venlafaxine. Approved Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Venlafaxine. Approved Ibuprofen Venlafaxine may increase the antiplatelet activities of Ibuprofen. Approved Ibutilide Venlafaxine may increase the QTc-prolonging activities of Ibutilide. Approved Icosapent Venlafaxine may increase the antiplatelet activities of Icosapent. Approved, Nutraceutical Icotinib The metabolism of Icotinib can be decreased when combined with Venlafaxine. Approved, Investigational Idarubicin The metabolism of Idarubicin can be decreased when combined with Venlafaxine. Approved Idelalisib The metabolism of Venlafaxine can be decreased when combined with Idelalisib. Approved Ifosfamide The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Venlafaxine resulting in a loss in efficacy. Approved Iloperidone Venlafaxine may increase the QTc-prolonging activities of Iloperidone. Approved Imatinib The serum concentration of Imatinib can be increased when it is combined with Venlafaxine. Approved Imidafenacin The metabolism of Imidafenacin can be decreased when combined with Venlafaxine. Approved, Investigational Imipramine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Imipramine. Approved Imiquimod The metabolism of Imiquimod can be decreased when combined with Venlafaxine. Approved, Investigational Indacaterol Venlafaxine may increase the tachycardic activities of Indacaterol. Approved Indalpine Venlafaxine may increase the serotonergic activities of Indalpine. Investigational, Withdrawn Indapamide The metabolism of Indapamide can be decreased when combined with Venlafaxine. Approved Indenolol The serum concentration of Indenolol can be increased when it is combined with Venlafaxine. Withdrawn Indinavir The serum concentration of Indinavir can be decreased when it is combined with Venlafaxine. Approved Indiplon The risk or severity of adverse effects can be increased when Indiplon is combined with Venlafaxine. Investigational Indomethacin Venlafaxine may increase the antiplatelet activities of Indomethacin. Approved, Investigational Insulin Aspart Venlafaxine may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Venlafaxine may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Venlafaxine may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Venlafaxine may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Venlafaxine may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Venlafaxine may increase the hypoglycemic activities of Insulin Lispro. Approved Iobenguane The therapeutic efficacy of Iobenguane can be decreased when used in combination with Venlafaxine. Approved, Investigational Ioflupane I-123 Venlafaxine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. Approved Ipecac The metabolism of Ipecac can be decreased when combined with Venlafaxine. Approved, Withdrawn Ipratropium The metabolism of Ipratropium bromide can be decreased when combined with Venlafaxine. Approved Iproclozide The risk or severity of adverse effects can be increased when Venlafaxine is combined with Iproclozide. Withdrawn Iproniazid Iproniazid may increase the serotonergic activities of Venlafaxine. Withdrawn Irbesartan The metabolism of Venlafaxine can be decreased when combined with Irbesartan. Approved, Investigational Irinotecan The metabolism of Irinotecan can be decreased when combined with Venlafaxine. Approved, Investigational Isavuconazole The serum concentration of Venlafaxine can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Isavuconazonium can be decreased when combined with Venlafaxine. Approved, Investigational Isocarboxazid The therapeutic efficacy of Venlafaxine can be increased when used in combination with Isocarboxazid. Approved Isoetarine Venlafaxine may increase the tachycardic activities of Isoetarine. Approved Isoflurane The metabolism of Isoflurane can be decreased when combined with Venlafaxine. Approved, Vet Approved Isometheptene Venlafaxine may increase the tachycardic activities of Isometheptene. Approved Isoniazid The metabolism of Venlafaxine can be decreased when combined with Isoniazid. Approved, Investigational Isoprenaline Venlafaxine may increase the tachycardic activities of Isoprenaline. Approved, Investigational Isosorbide Dinitrate The metabolism of Isosorbide Dinitrate can be decreased when combined with Venlafaxine. Approved, Investigational Isosorbide Mononitrate The metabolism of Isosorbide Mononitrate can be decreased when combined with Venlafaxine. Approved Isoxsuprine Venlafaxine may increase the tachycardic activities of Isoxsuprine. Approved, Withdrawn Isradipine The metabolism of Venlafaxine can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Venlafaxine can be decreased when combined with Itraconazole. Approved, Investigational Ivabradine The serum concentration of Ivabradine can be increased when it is combined with Venlafaxine. Approved Ivacaftor The serum concentration of Ivacaftor can be increased when it is combined with Venlafaxine. Approved Ivermectin The metabolism of Ivermectin can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Venlafaxine. Approved, Investigational Ixazomib The metabolism of Ixazomib can be decreased when combined with Venlafaxine. Approved, Investigational Ketamine The metabolism of Ketamine can be decreased when combined with Venlafaxine. Approved, Vet Approved Ketazolam The metabolism of Ketazolam can be decreased when combined with Venlafaxine. Approved Ketobemidone The metabolism of Ketobemidone can be decreased when combined with Venlafaxine. Approved, Investigational Ketoconazole The metabolism of Venlafaxine can be decreased when combined with Ketoconazole. Approved, Investigational Ketoprofen Venlafaxine may increase the antiplatelet activities of Ketoprofen. Approved, Vet Approved Ketorolac Venlafaxine may increase the antiplatelet activities of Ketorolac. Approved L-Tryptophan L-Tryptophan may increase the serotonergic activities of Venlafaxine. Approved, Nutraceutical, Withdrawn Labetalol The metabolism of Labetalol can be decreased when combined with Venlafaxine. Approved Lacidipine The metabolism of Lacidipine can be decreased when combined with Venlafaxine. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Lamotrigine. Approved, Investigational Landiolol The serum concentration of Landiolol can be increased when it is combined with Venlafaxine. Investigational Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Venlafaxine. Approved, Investigational Lapatinib The metabolism of Lapatinib can be decreased when combined with Venlafaxine. Approved, Investigational Laquinimod The metabolism of Laquinimod can be decreased when combined with Venlafaxine. Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Venlafaxine. Approved Leflunomide The metabolism of Venlafaxine can be decreased when combined with Leflunomide. Approved, Investigational Lenvatinib The metabolism of Lenvatinib can be decreased when combined with Venlafaxine. Approved, Investigational Lercanidipine The metabolism of Lercanidipine can be decreased when combined with Venlafaxine. Approved, Investigational Letermovir The metabolism of Letermovir can be decreased when combined with Venlafaxine. Approved, Investigational Letrozole The metabolism of Letrozole can be decreased when combined with Venlafaxine. Approved, Investigational Leuprolide Venlafaxine may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Venlafaxine. Approved, Investigational Levobetaxolol The serum concentration of Levobetaxolol can be increased when it is combined with Venlafaxine. Approved, Investigational Levobunolol The serum concentration of Levobunolol can be increased when it is combined with Venlafaxine. Approved Levobupivacaine The metabolism of Levobupivacaine can be decreased when combined with Venlafaxine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Levocabastine is combined with Venlafaxine. Approved, Investigational Levocetirizine The metabolism of Levocetirizine can be decreased when combined with Venlafaxine. Approved Levodopa The metabolism of Levodopa can be decreased when combined with Venlafaxine. Approved Levofloxacin Venlafaxine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Levomethadyl Acetate The metabolism of Levomethadyl Acetate can be decreased when combined with Venlafaxine. Approved, Investigational Levomilnacipran Venlafaxine may increase the serotonergic activities of Levomilnacipran. Approved, Investigational Levonordefrin Venlafaxine may decrease the antihypertensive activities of Levonordefrin. Approved Levonorgestrel The metabolism of Levonorgestrel can be decreased when combined with Venlafaxine. Approved, Investigational Levorphanol Levorphanol may increase the serotonergic activities of Venlafaxine. Approved Levosalbutamol Venlafaxine may increase the tachycardic activities of Levosalbutamol. Approved, Investigational Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Venlafaxine. Approved Lidocaine The metabolism of Lidocaine can be decreased when combined with Venlafaxine. Approved, Vet Approved Linezolid Linezolid may increase the serotonergic activities of Venlafaxine. Approved, Investigational Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Venlafaxine. Approved, Vet Approved Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Venlafaxine. Approved Liraglutide Venlafaxine may increase the hypoglycemic activities of Liraglutide. Approved Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Venlafaxine. Approved, Investigational Lithium cation Lithium may increase the serotonergic activities of Venlafaxine. Experimental Lobeglitazone The metabolism of Venlafaxine can be decreased when combined with Lobeglitazone. Approved, Investigational Lofentanil Lofentanil may increase the serotonergic activities of Venlafaxine. Illicit Lofexidine Venlafaxine may increase the tachycardic activities of Lofexidine. Approved, Investigational Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Venlafaxine. Approved, Investigational Lomustine The metabolism of Lomustine can be decreased when combined with Venlafaxine. Approved, Investigational Loperamide The metabolism of Loperamide can be decreased when combined with Venlafaxine. Approved Lopinavir The metabolism of Venlafaxine can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Loprazolam is combined with Venlafaxine. Experimental Loratadine The metabolism of Loratadine can be decreased when combined with Venlafaxine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Venlafaxine. Approved Lorcaserin The risk or severity of adverse effects can be increased when Venlafaxine is combined with Lorcaserin. Approved Lormetazepam The risk or severity of adverse effects can be increased when Lormetazepam is combined with Venlafaxine. Approved Lornoxicam Venlafaxine may increase the antiplatelet activities of Lornoxicam. Approved, Investigational Lorpiprazole The serum concentration of Venlafaxine can be increased when it is combined with Lorpiprazole. Approved Losartan The metabolism of Losartan can be decreased when combined with Venlafaxine. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Venlafaxine. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Venlafaxine. Approved Luliconazole The serum concentration of Venlafaxine can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Venlafaxine can be decreased when it is combined with Lumacaftor. Approved Lumefantrine Venlafaxine may increase the QTc-prolonging activities of Lumefantrine. Approved Lumiracoxib Venlafaxine may increase the antiplatelet activities of Lumiracoxib. Approved, Investigational Lurasidone The serum concentration of Lurasidone can be increased when it is combined with Venlafaxine. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Venlafaxine. Illicit, Investigational, Withdrawn Macimorelin The metabolism of Macimorelin can be decreased when combined with Venlafaxine. Approved, Investigational Macitentan The metabolism of Macitentan can be decreased when combined with Venlafaxine. Approved Magnesium salicylate Venlafaxine may increase the antiplatelet activities of Magnesium salicylate. Approved Magnesium sulfate The risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Venlafaxine. Approved, Investigational, Vet Approved Malathion The metabolism of Malathion can be decreased when combined with Venlafaxine. Approved, Investigational Manidipine The metabolism of Venlafaxine can be decreased when combined with Manidipine. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Venlafaxine is combined with Maprotiline. Approved, Investigational Maraviroc The metabolism of Maraviroc can be decreased when combined with Venlafaxine. Approved, Investigational Mebanazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Mebanazine. Withdrawn Mebendazole The metabolism of Mebendazole can be decreased when combined with Venlafaxine. Approved, Vet Approved Mebicar The risk or severity of adverse effects can be increased when Mebicar is combined with Venlafaxine. Experimental Mecasermin Venlafaxine may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Venlafaxine. Approved Meclofenamic acid Venlafaxine may increase the antiplatelet activities of Meclofenamic acid. Approved, Vet Approved Medazepam The risk or severity of adverse effects can be increased when Medazepam is combined with Venlafaxine. Experimental Medetomidine Venlafaxine may increase the tachycardic activities of Medetomidine. Vet Approved Medical Cannabis The metabolism of Medical Cannabis can be decreased when combined with Venlafaxine. Experimental, Investigational Medroxyprogesterone acetate The metabolism of Medroxyprogesterone acetate can be decreased when combined with Venlafaxine. Approved, Investigational Mefenamic acid Venlafaxine may increase the antiplatelet activities of Mefenamic acid. Approved Mefloquine The metabolism of Mefloquine can be decreased when combined with Venlafaxine. Approved, Investigational Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Venlafaxine. Approved, Nutraceutical, Vet Approved Meloxicam The metabolism of Meloxicam can be decreased when combined with Venlafaxine. Approved, Vet Approved Melperone The risk or severity of adverse effects can be increased when Melperone is combined with Venlafaxine. Approved, Investigational Mephentermine Venlafaxine may increase the tachycardic activities of Mephentermine. Approved Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Venlafaxine. Investigational, Withdrawn Mepindolol The serum concentration of Mepindolol can be increased when it is combined with Venlafaxine. Experimental Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Venlafaxine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Venlafaxine. Approved, Illicit Meptazinol Meptazinol may increase the serotonergic activities of Venlafaxine. Experimental Mequitazine The metabolism of Mequitazine can be decreased when combined with Venlafaxine. Approved Mesalazine Venlafaxine may increase the antiplatelet activities of Mesalazine. Approved Mesoridazine The metabolism of Mesoridazine can be decreased when combined with Venlafaxine. Approved, Investigational Metaraminol Venlafaxine may increase the tachycardic activities of Metaraminol. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine. Approved Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Venlafaxine. Experimental Metformin Venlafaxine may increase the hypoglycemic activities of Metformin. Approved Methadone The metabolism of Methadone can be decreased when combined with Venlafaxine. Approved Methadyl Acetate Methadyl Acetate may increase the serotonergic activities of Venlafaxine. Approved, Illicit Methamphetamine Venlafaxine may increase the tachycardic activities of Methamphetamine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Methapyrilene is combined with Venlafaxine. Withdrawn Methaqualone The metabolism of Methaqualone can be decreased when combined with Venlafaxine. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Venlafaxine. Approved Methotrimeprazine The metabolism of Venlafaxine can be decreased when combined with Methotrimeprazine. Approved, Investigational Methoxamine Venlafaxine may increase the tachycardic activities of Methoxamine. Approved, Investigational Methoxsalen The metabolism of Methoxsalen can be decreased when combined with Venlafaxine. Approved Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Methoxyphenamine Venlafaxine may increase the tachycardic activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Venlafaxine. Approved Methyclothiazide Venlafaxine may increase the hyponatremic activities of Methyclothiazide. Approved Methyldopa Venlafaxine may increase the tachycardic activities of Methyldopa. Approved Methylecgonine The risk or severity of adverse effects can be increased when Methylecgonine is combined with Venlafaxine. Experimental Methylene blue Venlafaxine may increase the serotonergic activities of Methylene blue. Approved, Investigational Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Venlafaxine. Approved Methylphenidate The metabolism of Methylphenidate can be decreased when combined with Venlafaxine. Approved, Investigational Methylphenobarbital The metabolism of Methylphenobarbital can be decreased when combined with Venlafaxine. Approved Methylprednisolone The metabolism of Methylprednisolone can be decreased when combined with Venlafaxine. Approved, Vet Approved Methyltestosterone The metabolism of Methyltestosterone can be decreased when combined with Venlafaxine. Approved Methyprylon The metabolism of Methyprylon can be decreased when combined with Venlafaxine. Approved, Illicit, Withdrawn Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Venlafaxine. Approved Metipranolol The serum concentration of Metipranolol can be increased when it is combined with Venlafaxine. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Venlafaxine. Approved, Investigational Metolazone Venlafaxine may increase the hyponatremic activities of Metolazone. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Venlafaxine. Approved, Investigational Metronidazole The metabolism of Metronidazole can be decreased when combined with Venlafaxine. Approved Metyrosine The risk or severity of adverse effects can be increased when Metyrosine is combined with Venlafaxine. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Venlafaxine. Experimental Mexiletine The metabolism of Mexiletine can be decreased when combined with Venlafaxine. Approved, Investigational Mianserin The metabolism of Mianserin can be decreased when combined with Venlafaxine. Approved, Investigational Mibefradil The metabolism of Mibefradil can be decreased when combined with Venlafaxine. Investigational, Withdrawn Miconazole The metabolism of Miconazole can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Midazolam The metabolism of Midazolam can be decreased when combined with Venlafaxine. Approved, Illicit Midecamycin The metabolism of Midecamycin can be decreased when combined with Venlafaxine. Approved Midodrine Venlafaxine may increase the tachycardic activities of Midodrine. Approved Midostaurin The metabolism of Venlafaxine can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Venlafaxine can be increased when it is combined with Mifepristone. Approved, Investigational Miglitol Venlafaxine may increase the hypoglycemic activities of Miglitol. Approved Milnacipran Venlafaxine may increase the serotonergic activities of Milnacipran. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Minaprine. Approved Mirabegron Venlafaxine may increase the tachycardic activities of Mirabegron. Approved Mirtazapine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Mirtazapine. Approved Mitotane The serum concentration of Venlafaxine can be decreased when it is combined with Mitotane. Approved Moclobemide The risk or severity of adverse effects can be increased when Venlafaxine is combined with Moclobemide. Approved, Investigational Modafinil The metabolism of Modafinil can be decreased when combined with Venlafaxine. Approved, Investigational Molindone The risk or severity of adverse effects can be increased when Molindone is combined with Venlafaxine. Approved Montelukast The metabolism of Montelukast can be decreased when combined with Venlafaxine. Approved Moperone The risk or severity of adverse effects can be increased when Venlafaxine is combined with Moperone. Experimental Morniflumate Venlafaxine may increase the antiplatelet activities of Morniflumate. Approved Morphine The metabolism of Morphine can be decreased when combined with Venlafaxine. Approved, Investigational Mosapramine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Mosapramine. Experimental Moxifloxacin Venlafaxine may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Moxonidine Venlafaxine may increase the tachycardic activities of Moxonidine. Approved, Investigational Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be decreased when combined with Venlafaxine. Approved, Investigational Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Venlafaxine. Approved, Investigational Nabiximols The metabolism of Nabiximols can be decreased when combined with Venlafaxine. Approved, Investigational Nabumetone Venlafaxine may increase the antiplatelet activities of Nabumetone. Approved Nadolol The serum concentration of Nadolol can be increased when it is combined with Venlafaxine. Approved Nalbuphine Nalbuphine may increase the serotonergic activities of Venlafaxine. Approved Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Venlafaxine. Approved Naloxone The metabolism of Naloxone can be decreased when combined with Venlafaxine. Approved, Vet Approved Naphazoline Venlafaxine may increase the tachycardic activities of Naphazoline. Approved Naproxen Venlafaxine may increase the antiplatelet activities of Naproxen. Approved, Vet Approved Naratriptan The risk or severity of adverse effects can be increased when Venlafaxine is combined with Naratriptan. Approved, Investigational Nateglinide The metabolism of Nateglinide can be decreased when combined with Venlafaxine. Approved, Investigational Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Venlafaxine. Approved, Investigational Nefazodone The metabolism of Venlafaxine can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Venlafaxine can be decreased when combined with Nelfinavir. Approved Nepafenac Venlafaxine may increase the antiplatelet activities of Nepafenac. Approved, Investigational Neratinib The metabolism of Neratinib can be decreased when combined with Venlafaxine. Approved, Investigational Netupitant The serum concentration of Venlafaxine can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Venlafaxine can be increased when combined with Nevirapine. Approved Nialamide Nialamide may increase the serotonergic activities of Venlafaxine. Withdrawn Nicardipine The metabolism of Venlafaxine can be decreased when combined with Nicardipine. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Venlafaxine. Approved, Investigational Nicomorphine Nicomorphine may increase the serotonergic activities of Venlafaxine. Experimental Nicotine The metabolism of Nicotine can be decreased when combined with Venlafaxine. Approved Nifedipine The metabolism of Nifedipine can be decreased when combined with Venlafaxine. Approved Niflumic Acid Venlafaxine may increase the antiplatelet activities of Niflumic Acid. Approved Nilotinib Venlafaxine may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Nilvadipine The metabolism of Nilvadipine can be decreased when combined with Venlafaxine. Approved, Investigational Nimesulide Venlafaxine may increase the antiplatelet activities of Nimesulide. Approved, Investigational, Withdrawn Nimodipine The serum concentration of Nimodipine can be increased when it is combined with Venlafaxine. Approved, Investigational Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Venlafaxine. Approved Nisoldipine The metabolism of Nisoldipine can be decreased when combined with Venlafaxine. Approved Nitrazepam The metabolism of Nitrazepam can be decreased when combined with Venlafaxine. Approved Nitrendipine The metabolism of Nitrendipine can be decreased when combined with Venlafaxine. Approved, Investigational Nitrofural The metabolism of Nitrofural can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Venlafaxine. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Nordazepam is combined with Venlafaxine. Approved Norepinephrine Venlafaxine may increase the tachycardic activities of Norepinephrine. Approved Norethisterone The metabolism of Norethisterone can be decreased when combined with Venlafaxine. Approved Norfenefrine Venlafaxine may increase the tachycardic activities of Norfenefrine. Experimental Norflurane The risk or severity of adverse effects can be increased when Norflurane is combined with Venlafaxine. Approved, Investigational Norgestrel The metabolism of Norgestrel can be decreased when combined with Venlafaxine. Approved Normethadone Normethadone may increase the serotonergic activities of Venlafaxine. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Venlafaxine is combined with Nortriptyline. Approved Nylidrin Venlafaxine may increase the tachycardic activities of Nylidrin. Approved Octamoxin The risk or severity of adverse effects can be increased when Venlafaxine is combined with Octamoxin. Withdrawn Octopamine Venlafaxine may increase the tachycardic activities of Octopamine. Experimental Odanacatib The metabolism of Odanacatib can be decreased when combined with Venlafaxine. Investigational Ofloxacin Venlafaxine may increase the QTc-prolonging activities of Ofloxacin. Approved Olanzapine Venlafaxine may increase the serotonergic activities of Olanzapine. Approved, Investigational Olaparib The serum concentration of Olaparib can be increased when it is combined with Venlafaxine. Approved Olodaterol Venlafaxine may increase the tachycardic activities of Olodaterol. Approved Olopatadine The metabolism of Olopatadine can be decreased when combined with Venlafaxine. Approved Omeprazole The metabolism of Omeprazole can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Ondansetron The metabolism of Ondansetron can be decreased when combined with Venlafaxine. Approved Opium Opium may increase the serotonergic activities of Venlafaxine. Approved, Illicit Orciprenaline Venlafaxine may increase the tachycardic activities of Orciprenaline. Approved Orphenadrine The metabolism of Orphenadrine can be decreased when combined with Venlafaxine. Approved Osanetant The risk or severity of adverse effects can be increased when Osanetant is combined with Venlafaxine. Investigational Osimertinib The serum concentration of Venlafaxine can be increased when it is combined with Osimertinib. Approved Ospemifene The metabolism of Ospemifene can be decreased when combined with Venlafaxine. Approved, Investigational Oxaprozin Venlafaxine may increase the antiplatelet activities of Oxaprozin. Approved Oxazepam The metabolism of Oxazepam can be decreased when combined with Venlafaxine. Approved Oxprenolol The serum concentration of Oxprenolol can be increased when it is combined with Venlafaxine. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Venlafaxine. Approved, Investigational Oxybutynin The metabolism of Oxybutynin can be decreased when combined with Venlafaxine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Venlafaxine is combined with Oxycodone. Approved, Illicit, Investigational Oxyfedrine Venlafaxine may increase the tachycardic activities of Oxyfedrine. Experimental Oxymetazoline Venlafaxine may increase the tachycardic activities of Oxymetazoline. Approved, Investigational Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Oxypertine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Oxypertine. Experimental Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Venlafaxine. Approved, Vet Approved Palbociclib The serum concentration of Venlafaxine can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone Venlafaxine may increase the QTc-prolonging activities of Paliperidone. Approved Palonosetron The metabolism of Palonosetron can be decreased when combined with Venlafaxine. Approved, Investigational Panobinostat The serum concentration of Venlafaxine can be increased when it is combined with Panobinostat. Approved, Investigational Pantoprazole The metabolism of Pantoprazole can be decreased when combined with Venlafaxine. Approved Paraldehyde The risk or severity of adverse effects can be increased when Paraldehyde is combined with Venlafaxine. Approved, Investigational Paramethadione The metabolism of Paramethadione can be decreased when combined with Venlafaxine. Approved Paramethasone The metabolism of Paramethasone can be decreased when combined with Venlafaxine. Approved Parecoxib Venlafaxine may increase the antiplatelet activities of Parecoxib. Approved Pargyline Pargyline may increase the serotonergic activities of Venlafaxine. Approved Paricalcitol The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. Approved, Investigational Paritaprevir The metabolism of Paritaprevir can be decreased when combined with Venlafaxine. Approved, Investigational Paroxetine The metabolism of Venlafaxine can be decreased when combined with Paroxetine. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Venlafaxine. Approved Peginterferon alfa-2b The serum concentration of Venlafaxine can be decreased when it is combined with Peginterferon alfa-2b. Approved Penbutolol The serum concentration of Penbutolol can be increased when it is combined with Venlafaxine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Penfluridol is combined with Venlafaxine. Experimental Pentamidine The metabolism of Pentamidine can be decreased when combined with Venlafaxine. Approved, Investigational Pentazocine Pentazocine may increase the serotonergic activities of Venlafaxine. Approved, Vet Approved Pentobarbital The metabolism of Venlafaxine can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel The metabolism of Perampanel can be decreased when combined with Venlafaxine. Approved Perazine The risk or severity of adverse effects can be increased when Perazine is combined with Venlafaxine. Approved, Investigational Perflutren Venlafaxine may increase the QTc-prolonging activities of Perflutren. Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Venlafaxine. Approved, Investigational, Vet Approved, Withdrawn Perhexiline The metabolism of Perhexiline can be decreased when combined with Venlafaxine. Approved, Investigational Permethrin The metabolism of Permethrin can be decreased when combined with Venlafaxine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Perospirone is combined with Venlafaxine. Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Venlafaxine. Approved Pethidine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Pethidine. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Venlafaxine. Withdrawn Phenazocine Phenazocine may increase the serotonergic activities of Venlafaxine. Experimental Phendimetrazine Venlafaxine may increase the tachycardic activities of Phendimetrazine. Approved, Illicit Phenelzine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenelzine. Approved Phenformin The metabolism of Phenformin can be decreased when combined with Venlafaxine. Approved, Investigational, Withdrawn Phenibut The risk or severity of adverse effects can be increased when Phenibut is combined with Venlafaxine. Experimental Phenindione The risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenindione. Approved, Investigational Pheniprazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Pheniprazine. Withdrawn Phenobarbital The metabolism of Venlafaxine can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine Phenoperidine may increase the serotonergic activities of Venlafaxine. Experimental Phenoxybenzamine The metabolism of Phenoxybenzamine can be decreased when combined with Venlafaxine. Approved Phenoxyethanol The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Venlafaxine. Approved Phenoxypropazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenoxypropazine. Withdrawn Phenprocoumon The risk or severity of adverse effects can be increased when Venlafaxine is combined with Phenprocoumon. Approved, Investigational Phenylbutazone Venlafaxine may increase the antiplatelet activities of Phenylbutazone. Approved, Vet Approved Phenylephrine Venlafaxine may increase the tachycardic activities of Phenylephrine. Approved Phenylpropanolamine Venlafaxine may increase the tachycardic activities of Phenylpropanolamine. Approved, Vet Approved, Withdrawn Phenytoin The metabolism of Venlafaxine can be increased when combined with Phenytoin. Approved, Vet Approved Pilocarpine The metabolism of Pilocarpine can be decreased when combined with Venlafaxine. Approved, Investigational Pimecrolimus The metabolism of Pimecrolimus can be decreased when combined with Venlafaxine. Approved, Investigational Pimozide The serum concentration of Pimozide can be increased when it is combined with Venlafaxine. Approved Pinacidil The metabolism of Pinacidil can be decreased when combined with Venlafaxine. Approved Pindolol Venlafaxine may increase the tachycardic activities of Pindolol. Approved, Investigational Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Venlafaxine. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Pipamperone is combined with Venlafaxine. Approved, Investigational Piperaquine The metabolism of Piperaquine can be decreased when combined with Venlafaxine. Approved, Investigational Piperazine The metabolism of Piperazine can be decreased when combined with Venlafaxine. Approved, Vet Approved Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Venlafaxine. Approved, Investigational Pirbuterol Venlafaxine may increase the tachycardic activities of Pirbuterol. Approved Piritramide Piritramide may increase the serotonergic activities of Venlafaxine. Approved, Investigational Pirlindole Pirlindole may increase the serotonergic activities of Venlafaxine. Approved Piroxicam Venlafaxine may increase the antiplatelet activities of Piroxicam. Approved, Investigational Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Venlafaxine. Approved Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Venlafaxine. Approved, Investigational Pivhydrazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Pivhydrazine. Withdrawn Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Venlafaxine. Approved Platelet Activating Factor The serum concentration of Platelet Activating Factor can be increased when it is combined with Venlafaxine. Experimental Podofilox The metabolism of Podofilox can be decreased when combined with Venlafaxine. Approved Polythiazide Venlafaxine may increase the hyponatremic activities of Polythiazide. Approved Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Venlafaxine. Approved Ponatinib The metabolism of Ponatinib can be decreased when combined with Venlafaxine. Approved, Investigational Posaconazole The metabolism of Venlafaxine can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Practolol The serum concentration of Practolol can be increased when it is combined with Venlafaxine. Approved Pramlintide Venlafaxine may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Pramocaine is combined with Venlafaxine. Approved Prasterone The metabolism of Prasterone can be decreased when combined with Venlafaxine. Approved, Investigational, Nutraceutical Prasugrel The metabolism of Prasugrel can be decreased when combined with Venlafaxine. Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Venlafaxine. Approved Prazepam The metabolism of Prazepam can be decreased when combined with Venlafaxine. Approved, Illicit Praziquantel The metabolism of Praziquantel can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Prednisolone The metabolism of Prednisolone can be decreased when combined with Venlafaxine. Approved, Vet Approved Prednisone The metabolism of Prednisone can be decreased when combined with Venlafaxine. Approved, Vet Approved Pregabalin The risk or severity of adverse effects can be increased when Pregabalin is combined with Venlafaxine. Approved, Illicit, Investigational Prenalterol Venlafaxine may increase the tachycardic activities of Prenalterol. Experimental Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Venlafaxine. Approved Primaquine The metabolism of Primaquine can be decreased when combined with Venlafaxine. Approved Primidone The metabolism of Venlafaxine can be increased when combined with Primidone. Approved, Vet Approved Procainamide Venlafaxine may increase the QTc-prolonging activities of Procainamide. Approved Procaine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Procaine. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Procarbazine. Approved, Investigational Procaterol Venlafaxine may increase the tachycardic activities of Procaterol. Approved, Investigational Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Venlafaxine. Approved, Vet Approved Progesterone The metabolism of Progesterone can be decreased when combined with Venlafaxine. Approved, Vet Approved Proguanil The metabolism of Proguanil can be decreased when combined with Venlafaxine. Approved Promazine The metabolism of Promazine can be decreased when combined with Venlafaxine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Promethazine. Approved, Investigational Propafenone The serum concentration of Venlafaxine can be increased when it is combined with Propafenone. Approved Propanidid The risk or severity of adverse effects can be increased when Propanidid is combined with Venlafaxine. Experimental Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine. Approved, Vet Approved Propericiazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Propericiazine. Approved, Investigational Propiverine The metabolism of Propiverine can be decreased when combined with Venlafaxine. Approved, Investigational Propofol The metabolism of Propofol can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Propoxycaine is combined with Venlafaxine. Approved Propranolol The metabolism of Propranolol can be decreased when combined with Venlafaxine. Approved, Investigational Prothipendyl The risk or severity of adverse effects can be increased when Venlafaxine is combined with Prothipendyl. Investigational Protokylol Venlafaxine may increase the tachycardic activities of Protokylol. Approved, Vet Approved Protriptyline The risk or severity of adverse effects can be increased when Venlafaxine is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Proxibarbal is combined with Venlafaxine. Experimental Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Venlafaxine. Approved PSD502 The risk or severity of adverse effects can be increased when PSD502 is combined with Venlafaxine. Investigational Pseudoephedrine Venlafaxine may increase the tachycardic activities of Pseudoephedrine. Approved Pyrazinamide The metabolism of Pyrazinamide can be decreased when combined with Venlafaxine. Approved, Investigational Pyrimethamine The metabolism of Venlafaxine can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quazepam The metabolism of Quazepam can be decreased when combined with Venlafaxine. Approved, Illicit Quetiapine Venlafaxine may increase the QTc-prolonging activities of Quetiapine. Approved Quinacrine The metabolism of Quinacrine can be decreased when combined with Venlafaxine. Approved, Investigational Quinethazone Venlafaxine may increase the hyponatremic activities of Quinethazone. Approved Quinidine The metabolism of Venlafaxine can be decreased when combined with Quinidine. Approved, Investigational Quinine Venlafaxine may increase the QTc-prolonging activities of Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Quinisocaine is combined with Venlafaxine. Experimental Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Venlafaxine. Approved, Investigational Racepinephrine Venlafaxine may increase the tachycardic activities of Racepinephrine. Approved Raclopride The risk or severity of adverse effects can be increased when Raclopride is combined with Venlafaxine. Investigational Ractopamine Venlafaxine may increase the tachycardic activities of Ractopamine. Vet Approved Raloxifene The metabolism of Raloxifene can be decreased when combined with Venlafaxine. Approved, Investigational Ramelteon The metabolism of Ramelteon can be decreased when combined with Venlafaxine. Approved, Investigational Ranitidine The metabolism of Ranitidine can be decreased when combined with Venlafaxine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Venlafaxine. Approved, Investigational Rasagiline The risk or severity of adverse effects can be increased when Venlafaxine is combined with Rasagiline. Approved Reboxetine The metabolism of Reboxetine can be decreased when combined with Venlafaxine. Approved, Investigational Regorafenib The metabolism of Regorafenib can be decreased when combined with Venlafaxine. Approved Remifentanil Remifentanil may increase the serotonergic activities of Venlafaxine. Approved Remoxipride The metabolism of Remoxipride can be decreased when combined with Venlafaxine. Approved, Withdrawn Repaglinide The metabolism of Repaglinide can be decreased when combined with Venlafaxine. Approved, Investigational Repinotan The metabolism of Repinotan can be decreased when combined with Venlafaxine. Investigational Reproterol Venlafaxine may increase the tachycardic activities of Reproterol. Investigational Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Venlafaxine. Approved, Investigational Resveratrol Venlafaxine may increase the antiplatelet activities of Resveratrol. Approved, Experimental, Investigational Retapamulin The metabolism of Retapamulin can be decreased when combined with Venlafaxine. Approved Rifabutin The metabolism of Venlafaxine can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Venlafaxine can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Venlafaxine can be increased when combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Venlafaxine. Approved, Investigational Rilmenidine Venlafaxine may increase the tachycardic activities of Rilmenidine. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Venlafaxine. Approved Rimiterol Venlafaxine may increase the tachycardic activities of Rimiterol. Experimental Rimonabant The metabolism of Rimonabant can be decreased when combined with Venlafaxine. Approved, Investigational Riociguat The metabolism of Riociguat can be decreased when combined with Venlafaxine. Approved Risperidone The metabolism of Risperidone can be decreased when combined with Venlafaxine. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Ritanserin is combined with Venlafaxine. Investigational Ritobegron Venlafaxine may increase the tachycardic activities of Ritobegron. Investigational Ritodrine Venlafaxine may increase the tachycardic activities of Ritodrine. Approved, Investigational Ritonavir The metabolism of Venlafaxine can be decreased when combined with Ritonavir. Approved, Investigational Rivaroxaban The metabolism of Rivaroxaban can be decreased when combined with Venlafaxine. Approved Rizatriptan The risk or severity of adverse effects can be increased when Venlafaxine is combined with Rizatriptan. Approved Rofecoxib Venlafaxine may increase the antiplatelet activities of Rofecoxib. Approved, Investigational, Withdrawn Rolapitant The metabolism of Rolapitant can be decreased when combined with Venlafaxine. Approved, Investigational Romidepsin The metabolism of Romidepsin can be decreased when combined with Venlafaxine. Approved, Investigational Romifidine Venlafaxine may increase the tachycardic activities of Romifidine. Vet Approved Ropinirole Venlafaxine may increase the tachycardic activities of Ropinirole. Approved, Investigational Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Venlafaxine. Approved Rosiglitazone Venlafaxine may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Venlafaxine. Approved Rotigotine The metabolism of Rotigotine can be decreased when combined with Venlafaxine. Approved Roxithromycin The metabolism of Roxithromycin can be decreased when combined with Venlafaxine. Approved, Investigational, Withdrawn Rucaparib The metabolism of Rucaparib can be decreased when combined with Venlafaxine. Approved, Investigational Rupatadine The metabolism of Rupatadine can be decreased when combined with Venlafaxine. Approved Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Venlafaxine. Approved Safinamide The metabolism of Safinamide can be decreased when combined with Venlafaxine. Approved, Investigational Safrazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Safrazine. Withdrawn Salbutamol Venlafaxine may increase the tachycardic activities of Salbutamol. Approved, Vet Approved Salicylic acid Venlafaxine may increase the antiplatelet activities of Salicylic acid. Approved, Investigational, Vet Approved Salmeterol The serum concentration of Salmeterol can be increased when it is combined with Venlafaxine. Approved Salsalate Venlafaxine may increase the antiplatelet activities of Salsalate. Approved Saquinavir The metabolism of Venlafaxine can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Venlafaxine can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The serum concentration of Saxagliptin can be increased when it is combined with Venlafaxine. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine. Approved, Investigational Secobarbital The metabolism of Venlafaxine can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Venlafaxine is combined with Selegiline. Approved, Investigational, Vet Approved Selexipag The metabolism of Selexipag can be decreased when combined with Venlafaxine. Approved Seliciclib Venlafaxine may increase the antiplatelet activities of Seliciclib. Investigational Sepranolone The risk or severity of adverse effects can be increased when Sepranolone is combined with Venlafaxine. Investigational Seratrodast The metabolism of Seratrodast can be decreased when combined with Venlafaxine. Approved Sertindole The metabolism of Sertindole can be decreased when combined with Venlafaxine. Approved, Investigational, Withdrawn Sertraline Venlafaxine may increase the serotonergic activities of Sertraline. Approved Sevoflurane The metabolism of Sevoflurane can be decreased when combined with Venlafaxine. Approved, Vet Approved Sibutramine The metabolism of Sibutramine can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational, Withdrawn Sildenafil The metabolism of Venlafaxine can be decreased when combined with Sildenafil. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Venlafaxine. Approved Siltuximab The serum concentration of Venlafaxine can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Venlafaxine can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Venlafaxine. Approved Sirolimus The metabolism of Sirolimus can be decreased when combined with Venlafaxine. Approved, Investigational Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Venlafaxine. Approved, Investigational Sodium oxybate The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Venlafaxine. Approved Solabegron Venlafaxine may increase the tachycardic activities of Solabegron. Investigational Solifenacin The metabolism of Solifenacin can be decreased when combined with Venlafaxine. Approved Sonidegib The serum concentration of Sonidegib can be increased when it is combined with Venlafaxine. Approved, Investigational Sorafenib The metabolism of Sorafenib can be decreased when combined with Venlafaxine. Approved, Investigational Sotalol Venlafaxine may increase the QTc-prolonging activities of Sotalol. Approved Sparteine The metabolism of Sparteine can be decreased when combined with Venlafaxine. Experimental Spiramycin The metabolism of Spiramycin can be decreased when combined with Venlafaxine. Approved St. John's Wort The serum concentration of Venlafaxine can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Venlafaxine can be increased when it is combined with Stiripentol. Approved Sufentanil The metabolism of Sufentanil can be decreased when combined with Venlafaxine. Approved, Investigational Sulfadiazine The metabolism of Venlafaxine can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Sulfamethoxazole can be decreased when combined with Venlafaxine. Approved Sulfasalazine Venlafaxine may increase the antiplatelet activities of Sulfasalazine. Approved Sulfinpyrazone The metabolism of Sulfinpyrazone can be decreased when combined with Venlafaxine. Approved Sulfisoxazole The metabolism of Venlafaxine can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulindac Venlafaxine may increase the antiplatelet activities of Sulindac. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Venlafaxine. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Sultopride is combined with Venlafaxine. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Venlafaxine is combined with Sumatriptan. Approved, Investigational Sunitinib The metabolism of Sunitinib can be decreased when combined with Venlafaxine. Approved, Investigational Suprofen Venlafaxine may increase the antiplatelet activities of Suprofen. Approved, Withdrawn Suvorexant The serum concentration of Suvorexant can be increased when it is combined with Venlafaxine. Approved, Investigational Synephrine Venlafaxine may increase the tachycardic activities of Synephrine. Experimental Synthetic Conjugated Estrogens, A The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Venlafaxine. Approved Synthetic Conjugated Estrogens, B The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Venlafaxine. Approved Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Venlafaxine. Approved, Investigational Tadalafil The metabolism of Tadalafil can be decreased when combined with Venlafaxine. Approved, Investigational Talinolol The serum concentration of Talinolol can be increased when it is combined with Venlafaxine. Investigational Talniflumate Venlafaxine may increase the antiplatelet activities of Talniflumate. Approved Tamoxifen The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Venlafaxine resulting in a loss in efficacy. Approved Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Venlafaxine. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Tandospirone is combined with Venlafaxine. Investigational Tapentadol The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tapentadol. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Venlafaxine. Approved, Investigational Tasosartan The metabolism of Tasosartan can be decreased when combined with Venlafaxine. Approved Taurochenodeoxycholic acid The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Venlafaxine. Experimental Tedizolid phosphate Tedizolid Phosphate may increase the serotonergic activities of Venlafaxine. Approved Tegaserod The metabolism of Tegaserod can be decreased when combined with Venlafaxine. Approved, Investigational, Withdrawn Telaprevir The metabolism of Venlafaxine can be decreased when combined with Telaprevir. Approved, Withdrawn Telavancin Venlafaxine may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin The metabolism of Venlafaxine can be decreased when combined with Telithromycin. Approved Temazepam The metabolism of Temazepam can be decreased when combined with Venlafaxine. Approved, Investigational Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Venlafaxine. Approved Teniposide The metabolism of Teniposide can be decreased when combined with Venlafaxine. Approved Tenoxicam Venlafaxine may increase the antiplatelet activities of Tenoxicam. Approved Terbinafine The metabolism of Venlafaxine can be decreased when combined with Terbinafine. Approved, Investigational, Vet Approved Terbutaline Venlafaxine may increase the tachycardic activities of Terbutaline. Approved Terfenadine The metabolism of Terfenadine can be decreased when combined with Venlafaxine. Approved, Withdrawn Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Venlafaxine. Experimental Tertatolol The serum concentration of Tertatolol can be increased when it is combined with Venlafaxine. Experimental Tesmilifene The metabolism of Tesmilifene can be decreased when combined with Venlafaxine. Investigational Testosterone The metabolism of Testosterone can be decreased when combined with Venlafaxine. Approved, Investigational Testosterone cypionate The metabolism of Testosterone cypionate can be decreased when combined with Venlafaxine. Approved Testosterone enanthate The metabolism of Testosterone enanthate can be decreased when combined with Venlafaxine. Approved Testosterone propionate The metabolism of Testosterone propionate can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The metabolism of Testosterone undecanoate can be decreased when combined with Venlafaxine. Approved, Investigational Tetrabenazine Venlafaxine may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Tetracaine is combined with Venlafaxine. Approved, Vet Approved Tetracycline The metabolism of Tetracycline can be decreased when combined with Venlafaxine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Venlafaxine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Venlafaxine. Investigational Tetryzoline Venlafaxine may increase the tachycardic activities of Tetryzoline. Approved Tezacaftor The metabolism of Tezacaftor can be decreased when combined with Venlafaxine. Approved, Investigational Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Venlafaxine. Approved, Investigational, Withdrawn Theophylline The metabolism of Theophylline can be decreased when combined with Venlafaxine. Approved Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Venlafaxine. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Venlafaxine. Approved, Vet Approved Thiopropazate The risk or severity of adverse effects can be increased when Venlafaxine is combined with Thiopropazate. Experimental Thioproperazine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Thioproperazine. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Venlafaxine. Approved, Withdrawn Thiotepa The metabolism of Thiotepa can be decreased when combined with Venlafaxine. Approved, Investigational Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Venlafaxine. Approved Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Venlafaxine. Approved Tiagabine The metabolism of Tiagabine can be decreased when combined with Venlafaxine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Tiapride is combined with Venlafaxine. Approved, Investigational Tiaprofenic acid Venlafaxine may increase the antiplatelet activities of Tiaprofenic acid. Approved Ticagrelor The metabolism of Ticagrelor can be decreased when combined with Venlafaxine. Approved Ticlopidine The metabolism of Venlafaxine can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Tiletamine is combined with Venlafaxine. Vet Approved Tilidine Tilidine may increase the serotonergic activities of Venlafaxine. Experimental Timolol The metabolism of Timolol can be decreased when combined with Venlafaxine. Approved Tinidazole The metabolism of Tinidazole can be decreased when combined with Venlafaxine. Approved, Investigational Tioclomarol The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tioclomarol. Experimental Tiotropium The metabolism of Tiotropium can be decreased when combined with Venlafaxine. Approved Tipranavir The metabolism of Venlafaxine can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine Venlafaxine may increase the tachycardic activities of Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Venlafaxine can be decreased when it is combined with Tocilizumab. Approved Tocofersolan The metabolism of Tocofersolan can be decreased when combined with Venlafaxine. Approved Tocopherol The metabolism of Tocopherol can be decreased when combined with Venlafaxine. Approved, Investigational Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Venlafaxine. Approved, Investigational Tolazamide Venlafaxine may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide The metabolism of Venlafaxine can be decreased when combined with Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Venlafaxine. Approved, Withdrawn Tolmetin Venlafaxine may increase the antiplatelet activities of Tolmetin. Approved Toloxatone Toloxatone may increase the serotonergic activities of Venlafaxine. Approved Tolterodine The metabolism of Tolterodine can be decreased when combined with Venlafaxine. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Venlafaxine. Approved Topiramate The metabolism of Venlafaxine can be decreased when combined with Topiramate. Approved Topiroxostat The metabolism of Venlafaxine can be decreased when combined with Topiroxostat. Approved, Investigational Topotecan The serum concentration of Topotecan can be increased when it is combined with Venlafaxine. Approved, Investigational Toremifene Venlafaxine may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Trabectedin The metabolism of Trabectedin can be decreased when combined with Venlafaxine. Approved, Investigational Tramadol Venlafaxine may increase the neuroexcitatory activities of Tramadol. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Tranylcypromine. Approved, Investigational Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Venlafaxine. Approved, Investigational Trazodone Venlafaxine may increase the serotonergic activities of Trazodone. Approved, Investigational Tretinoin The metabolism of Tretinoin can be decreased when combined with Venlafaxine. Approved, Investigational, Nutraceutical Tretoquinol Venlafaxine may increase the tachycardic activities of Tretoquinol. Experimental Triamcinolone The metabolism of Triamcinolone can be decreased when combined with Venlafaxine. Approved, Vet Approved Triazolam The metabolism of Triazolam can be decreased when combined with Venlafaxine. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Venlafaxine. Vet Approved Trichlormethiazide Venlafaxine may increase the hyponatremic activities of Trichlormethiazide. Approved, Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Venlafaxine. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Venlafaxine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Trifluperidol is combined with Venlafaxine. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Venlafaxine. Approved, Vet Approved Trimethadione The metabolism of Trimethadione can be decreased when combined with Venlafaxine. Approved Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Venlafaxine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Venlafaxine. Approved Troglitazone The metabolism of Troglitazone can be decreased when combined with Venlafaxine. Investigational, Withdrawn Trolamine salicylate Venlafaxine may increase the antiplatelet activities of Trolamine salicylate. Approved Troleandomycin The metabolism of Troleandomycin can be decreased when combined with Venlafaxine. Approved Tropisetron Tropisetron may increase the serotonergic activities of Venlafaxine. Approved, Investigational Tulobuterol Venlafaxine may increase the tachycardic activities of Tulobuterol. Investigational Udenafil The metabolism of Udenafil can be decreased when combined with Venlafaxine. Approved, Investigational Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Venlafaxine. Approved Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Venlafaxine. Approved Valbenazine The metabolism of Valbenazine can be decreased when combined with Venlafaxine. Approved, Investigational Valdecoxib Venlafaxine may increase the antiplatelet activities of Valdecoxib. Approved, Investigational, Withdrawn Valproic Acid The metabolism of Venlafaxine can be decreased when combined with Valproic Acid. Approved, Investigational Valsartan The metabolism of Venlafaxine can be decreased when combined with Valsartan. Approved, Investigational Vandetanib Venlafaxine may increase the QTc-prolonging activities of Vandetanib. Approved Vanoxerine The metabolism of Vanoxerine can be decreased when combined with Venlafaxine. Investigational Vardenafil The metabolism of Vardenafil can be decreased when combined with Venlafaxine. Approved Velpatasvir The metabolism of Velpatasvir can be decreased when combined with Venlafaxine. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Venlafaxine. Approved Venetoclax The metabolism of Venetoclax can be decreased when combined with Venlafaxine. Approved, Investigational Veralipride The risk or severity of adverse effects can be increased when Veralipride is combined with Venlafaxine. Experimental Verapamil The metabolism of Verapamil can be decreased when combined with Venlafaxine. Approved Vernakalant The metabolism of Vernakalant can be decreased when combined with Venlafaxine. Approved, Investigational Vicriviroc The metabolism of Vicriviroc can be decreased when combined with Venlafaxine. Investigational Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine. Approved Vilanterol Venlafaxine may increase the tachycardic activities of Vilanterol. Approved Vilazodone The serum concentration of Vilazodone can be increased when it is combined with Venlafaxine. Approved Vinblastine The metabolism of Vinblastine can be decreased when combined with Venlafaxine. Approved Vincristine The metabolism of Vincristine can be decreased when combined with Venlafaxine. Approved, Investigational Vindesine The serum concentration of Vindesine can be increased when it is combined with Venlafaxine. Approved, Investigational Vinflunine The metabolism of Vinflunine can be decreased when combined with Venlafaxine. Approved, Investigational Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Venlafaxine. Approved, Investigational Vinyl ether The risk or severity of adverse effects can be increased when Vinyl ether is combined with Venlafaxine. Experimental Vismodegib The metabolism of Vismodegib can be decreased when combined with Venlafaxine. Approved, Investigational Voriconazole The risk or severity of adverse effects can be increased when Voriconazole is combined with Venlafaxine. Approved, Investigational Vortioxetine Venlafaxine may increase the serotonergic activities of Vortioxetine. Approved, Investigational Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Venlafaxine. Approved, Investigational Warfarin The risk or severity of adverse effects can be increased when Venlafaxine is combined with Warfarin. Approved Xamoterol Venlafaxine may increase the tachycardic activities of Xamoterol. Experimental Xenon The risk or severity of adverse effects can be increased when Xenon is combined with Venlafaxine. Experimental Xylazine Venlafaxine may increase the tachycardic activities of Xylazine. Vet Approved Xylometazoline Venlafaxine may increase the tachycardic activities of Xylometazoline. Approved, Investigational Yohimbine The metabolism of Yohimbine can be decreased when combined with Venlafaxine. Approved, Investigational, Vet Approved Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Venlafaxine. Approved, Investigational Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Venlafaxine. Approved, Investigational Zaleplon The metabolism of Zaleplon can be decreased when combined with Venlafaxine. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Venlafaxine. Approved Zidovudine The metabolism of Zidovudine can be decreased when combined with Venlafaxine. Approved Zileuton The metabolism of Zileuton can be decreased when combined with Venlafaxine. Approved, Investigational, Withdrawn Zimelidine Venlafaxine may increase the serotonergic activities of Zimelidine. Withdrawn Ziprasidone Venlafaxine may increase the QTc-prolonging activities of Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Zolazepam is combined with Venlafaxine. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Venlafaxine is combined with Zolmitriptan. Approved, Investigational Zolpidem The metabolism of Zolpidem can be decreased when combined with Venlafaxine. Approved Zomepirac The metabolism of Zomepirac can be decreased when combined with Venlafaxine. Withdrawn Zonisamide The metabolism of Zonisamide can be decreased when combined with Venlafaxine. Approved, Investigational Zopiclone The serum concentration of Zopiclone can be increased when it is combined with Venlafaxine. Approved Zotepine The risk or severity of adverse effects can be increased when Zotepine is combined with Venlafaxine. Approved, Investigational, Withdrawn Zucapsaicin The metabolism of Venlafaxine can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol The serum concentration of Zuclopenthixol can be increased when it is combined with Venlafaxine. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Avoid St.John's Wort.
- Take with food.
References
- Synthesis Reference
Thomas P. Jerussi, Chrisantha H. Senanayake, "Derivatives of (+)-venlafaxine and methods of preparing and using the same." U.S. Patent US6197828, issued June, 1994.
US6197828- General References
- Golden RN, Nicholas L: Antidepressant efficacy of venlafaxine. Depress Anxiety. 2000;12 Suppl 1:45-9. [PubMed:11098413]
- Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA: A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006 Oct;26(5):482-8. [PubMed:16974189]
- Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 Sep;65(9):1190-6. [PubMed:15367045]
- Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004 Aug;110(3):697-706. [PubMed:15288411]
- Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R: The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005 Feb;45(2):144-52. [PubMed:15705120]
- Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96. [PubMed:22992668]
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- External Links
- Human Metabolome Database
- HMDB0061166
- KEGG Drug
- D08670
- KEGG Compound
- C07187
- PubChem Compound
- 5656
- PubChem Substance
- 46504593
- ChemSpider
- 5454
- BindingDB
- 82071
- ChEBI
- 9943
- ChEMBL
- CHEMBL637
- Therapeutic Targets Database
- DAP000054
- PharmGKB
- PA451866
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Venlafaxine
- ATC Codes
- N06AX16 — Venlafaxine
- AHFS Codes
- 28:16.04.16 — Selective Serotonin and Norepinephrine-reuptake Inhibitors
- FDA label
- Download (3.38 MB)
- MSDS
- Download (36.5 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Wyeth pharmaceuticals inc
- Teva pharmaceuticals usa inc
- Osmotica pharmaceutical corp
- Actavis totowa llc
- Amneal pharmaceuticals
- Aurobindo pharma ltd
- Caraco pharmaceutical laboratories ltd
- Dr reddys laboratories ltd
- Mylan pharmaceuticals inc
- Pliva hrvatska doo
- Sandoz inc
- Vintage pharmaceuticals llc
- Zydus pharmaceuticals usa inc
- Wyeth
- Packagers
- Advanced Pharmaceutical Services Inc.
- Amerisource Health Services Corp.
- AQ Pharmaceuticals Inc.
- A-S Medication Solutions LLC
- Bryant Ranch Prepack
- Cadila Healthcare Ltd.
- Caraco Pharmaceutical Labs
- Cardinal Health
- Caremark LLC
- Direct Pharmaceuticals Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Doctor Reddys Laboratories Ltd.
- Heartland Repack Services LLC
- Innoviant Pharmacy Inc.
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Rebel Distributors Corp.
- Remedy Repack
- Resource Optimization and Innovation LLC
- Schwarz Pharma Inc.
- Southwood Pharmaceuticals
- Stat Rx Usa
- Teva Pharmaceutical Industries Ltd.
- Tya Pharmaceuticals
- UDL Laboratories
- Upstate Pharma LLC
- Vangard Labs Inc.
- Wyeth Pharmaceuticals
- Zydus Pharmaceuticals
- Dosage forms
Form Route Strength Capsule, extended release Oral 150.0 mg Capsule, extended release Oral 75.0 mg Tablet Oral 37.5 mg Tablet Oral 50 mg Tablet Oral 75 mg Capsule, extended release Oral 150 mg Capsule, extended release Oral 150 mg/1 Capsule, extended release Oral 37.5 mg Capsule, extended release Oral 37.5 mg/1 Capsule, extended release Oral 75 mg/1 Capsule, extended release Oral 75 mg Tablet Oral 100 mg/1 Tablet Oral 25 mg/1 Tablet Oral 37.5 mg/1 Tablet Oral 50 mg/1 Tablet Oral 75 mg/1 Capsule, coated, extended release Oral 75 mg/1 Capsule, delayed release Oral 75 mg/1 Tablet, extended release Oral 150 mg/1 Tablet, extended release Oral 225 mg/1 Tablet, extended release Oral 37.5 mg/1 Tablet, extended release Oral 75 mg/1 Tablet, film coated, extended release Oral 150 mg/1 Tablet, film coated, extended release Oral 225 mg/1 Tablet, film coated, extended release Oral 37.5 mg/1 Tablet, film coated, extended release Oral 75 mg/1 - Prices
Unit description Cost Unit Venlafaxine HCl 30 225 mg 24 Hour tablet Bottle 276.98USD bottle Effexor XR 30 37.5 mg 24 Hour Capsule Bottle 144.33USD bottle Venlafaxine HCl 30 37.5 mg 24 Hour tablet Bottle 114.46USD bottle Effexor 30 75 mg tablet Bottle 87.83USD bottle Effexor 30 25 mg tablet Bottle 74.82USD bottle Effexor XR 150 mg 24 Hour Capsule 5.87USD capsule Effexor xr 150 mg capsule 5.65USD capsule Effexor XR 75 mg 24 Hour Capsule 5.39USD capsule Effexor xr 75 mg capsule 4.76USD capsule Venlafaxine HCl 150 mg 24 Hour tablet 4.72USD tablet Effexor xr 37.5 mg capsule 4.63USD capsule Venlafaxine HCl 75 mg 24 Hour tablet 4.42USD tablet Effexor 100 mg tablet 2.92USD tablet Effexor 75 mg tablet 2.7USD tablet Effexor 50 mg tablet 2.6USD tablet Effexor 37.5 mg tablet 2.5USD tablet Effexor 25 mg tablet 2.4USD tablet Venlafaxine hcl 100 mg tablet 2.36USD tablet Venlafaxine hcl 75 mg tablet 2.23USD tablet Effexor Xr 150 mg Extended-Release Capsule 2.16USD capsule Venlafaxine hcl 50 mg tablet 2.1USD tablet Effexor Xr 75 mg Extended-Release Capsule 2.05USD capsule Venlafaxine hcl 37.5 mg tablet 2.04USD tablet Venlafaxine hcl 25 mg tablet 1.98USD tablet Apo-Venlafaxine Xr 150 mg Extended-Release Capsule 1.2USD capsule Co Venlafaxine Xr 150 mg Extended-Release Capsule 1.2USD capsule Mylan-Venlafaxine Xr 150 mg Extended-Release Capsule 1.2USD capsule Novo-Venlafaxine Xr 150 mg Extended-Release Capsule 1.2USD capsule Pms-Venlafaxine Xr 150 mg Extended-Release Capsule 1.2USD capsule Ratio-Venlafaxine Xr 150 mg Extended-Release Capsule 1.2USD capsule Sandoz Venlafaxine Xr 150 mg Extended-Release Capsule 1.2USD capsule Apo-Venlafaxine Xr 75 mg Extended-Release Capsule 1.14USD capsule Co Venlafaxine Xr 75 mg Extended-Release Capsule 1.14USD capsule Mylan-Venlafaxine Xr 75 mg Extended-Release Capsule 1.14USD capsule Novo-Venlafaxine Xr 75 mg Extended-Release Capsule 1.14USD capsule Pms-Venlafaxine Xr 75 mg Extended-Release Capsule 1.14USD capsule Ratio-Venlafaxine Xr 75 mg Extended-Release Capsule 1.14USD capsule Sandoz Venlafaxine Xr 75 mg Extended-Release Capsule 1.14USD capsule Effexor Xr 37.5 mg Extended-Release Capsule 1.02USD capsule Apo-Venlafaxine Xr 37.5 mg Extended-Release Capsule 0.57USD capsule Co Venlafaxine Xr 37.5 mg Extended-Release Capsule 0.57USD capsule Mylan-Venlafaxine Xr 37.5 mg Extended-Release Capsule 0.57USD capsule Novo-Venlafaxine Xr 37.5 mg Extended-Release Capsule 0.57USD capsule Pms-Venlafaxine Xr 37.5 mg Extended-Release Capsule 0.57USD capsule Ratio-Venlafaxine Xr 37.5 mg Extended-Release Capsule 0.57USD capsule Sandoz Venlafaxine Xr 37.5 mg Extended-Release Capsule 0.57USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5916923 No 1993-06-28 2013-06-28 US CA2126305 No 2006-10-17 2014-06-20 Canada CA2199778 No 2005-12-20 2017-03-12 Canada US6403120 Yes 1997-09-20 2017-09-20 US US6419958 Yes 1997-09-20 2017-09-20 US US6274171 Yes 1997-09-20 2017-09-20 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 215-217 °C (Hydrochloride salt) Not Available water solubility 572 mg/ml (Hydrochloride salt) Not Available - Predicted Properties
Property Value Source Water Solubility 0.23 mg/mL ALOGPS logP 2.69 ALOGPS logP 2.74 ChemAxon logS -3.1 ALOGPS pKa (Strongest Acidic) 14.42 ChemAxon pKa (Strongest Basic) 8.91 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 32.7 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 83.02 m3·mol-1 ChemAxon Polarizability 32.33 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9782 Blood Brain Barrier + 0.9382 Caco-2 permeable + 0.852 P-glycoprotein substrate Substrate 0.6534 P-glycoprotein inhibitor I Inhibitor 0.7031 P-glycoprotein inhibitor II Inhibitor 0.8031 Renal organic cation transporter Non-inhibitor 0.5792 CYP450 2C9 substrate Non-substrate 0.7583 CYP450 2D6 substrate Substrate 0.8919 CYP450 3A4 substrate Substrate 0.7407 CYP450 1A2 substrate Non-inhibitor 0.7664 CYP450 2C9 inhibitor Non-inhibitor 0.6876 CYP450 2D6 inhibitor Inhibitor 0.7287 CYP450 2C19 inhibitor Non-inhibitor 0.7199 CYP450 3A4 inhibitor Non-inhibitor 0.8308 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8666 Ames test Non AMES toxic 0.8 Carcinogenicity Non-carcinogens 0.6762 Biodegradation Not ready biodegradable 0.9941 Rat acute toxicity 2.5404 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5486 hERG inhibition (predictor II) Inhibitor 0.6627
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenol ethers
- Sub Class
- Anisoles
- Direct Parent
- Anisoles
- Alternative Parents
- Phenoxy compounds / Methoxybenzenes / Cyclohexanols / Aralkylamines / Alkyl aryl ethers / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Cyclic alcohols and derivatives / Organopnictogen compounds show 1 more
- Substituents
- Phenoxy compound / Anisole / Methoxybenzene / Alkyl aryl ether / Aralkylamine / Cyclohexanol / Monocyclic benzene moiety / 1,3-aminoalcohol / Tertiary alcohol / Cyclic alcohol show 12 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- tertiary alcohol, tertiary amino compound, monomethoxybenzene, cyclohexanols (CHEBI:9943)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serotonin:sodium symporter activity
- Specific Function
- Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
- Gene Name
- SLC6A4
- Uniprot ID
- P31645
- Uniprot Name
- Sodium-dependent serotonin transporter
- Molecular Weight
- 70324.165 Da
References
- Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064]
- Gould GG, Altamirano AV, Javors MA, Frazer A: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry. 2006 Mar 1;59(5):408-14. Epub 2005 Sep 2. [PubMed:16140280]
- Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, Seibyl JP, Rogers JF: Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007 Feb;27(1):71-5. [PubMed:17224717]
- Malizia AL, Melichar JM, Brown DJ, Gunn RN, Reynolds A, Jones T, Nutt DJ: Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo. J Psychopharmacol. 1997;11(3):279-81. [PubMed:9305421]
- Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
- Van Ameringen M, Mancini C, Patterson B, Simpson W: Pharmacotherapy for social anxiety disorder: an update. Isr J Psychiatry Relat Sci. 2009;46(1):53-61. [PubMed:19728573]
- Beique J, de Montigny C, Blier P, Debonnel G: Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology. 2000 Jul 24;39(10):1800-12. [PubMed:10884561]
- Westenberg HG: Recent advances in understanding and treating social anxiety disorder. CNS Spectr. 2009 Feb;14(2 Suppl 3):24-33. [PubMed:19238127]
- Sindrup SH, Otto M, Finnerup NB, Jensen TS: Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):399-409. [PubMed:15910402]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Norepinephrine:sodium symporter activity
- Specific Function
- Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A2
- Uniprot ID
- P23975
- Uniprot Name
- Sodium-dependent noradrenaline transporter
- Molecular Weight
- 69331.42 Da
References
- Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476]
- Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7. [PubMed:16893531]
- Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32. [PubMed:9669506]
- Van Ameringen M, Mancini C, Patterson B, Simpson W: Pharmacotherapy for social anxiety disorder: an update. Isr J Psychiatry Relat Sci. 2009;46(1):53-61. [PubMed:19728573]
- Beique J, de Montigny C, Blier P, Debonnel G: Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology. 2000 Jul 24;39(10):1800-12. [PubMed:10884561]
- Westenberg HG: Recent advances in understanding and treating social anxiety disorder. CNS Spectr. 2009 Feb;14(2 Suppl 3):24-33. [PubMed:19238127]
- Sindrup SH, Otto M, Finnerup NB, Jensen TS: Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):399-409. [PubMed:15910402]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Monoamine transmembrane transporter activity
- Specific Function
- Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A3
- Uniprot ID
- Q01959
- Uniprot Name
- Sodium-dependent dopamine transporter
- Molecular Weight
- 68494.255 Da
References
- Dawson LA, Nguyen HQ, Geiger A: Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. Neuropharmacology. 1999 Aug;38(8):1153-63. [PubMed:10462128]
- Bourin M: [Psychopharmacological profile of venlafaxine]. Encephale. 1999 Jun;25 Spec No 2:21-2; discussion 23-5. [PubMed:10434156]
- Barkin RL, Fawcett J: The management challenges of chronic pain: the role of antidepressants. Am J Ther. 2000 Jan;7(1):31-47. [PubMed:11319571]
- Lemke MR: [Antidepressant effects of dopamine agonists. Experimental and clinical findings]. Nervenarzt. 2007 Jan;78(1):31-8. [PubMed:17187269]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ: O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90. [PubMed:10192828]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]
- Uhr M, Grauer MT, Holsboer F: Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry. 2003 Oct 15;54(8):840-6. [PubMed:14550684]
- Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, Kugelberg FC, Hiemke C: Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol. 2010 Sep;20(9):632-40. doi: 10.1016/j.euroneuro.2010.04.004. Epub 2010 May 13. [PubMed:20466523]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM: Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos. 2011 May;32(4):233-44. doi: 10.1002/bdd.753. Epub 2011 Mar 28. [PubMed:21446053]
Drug created on June 13, 2005 07:24 / Updated on July 22, 2018 19:24